

NAME: John D. Reveille

PRESENT TITLE: Professor of Medicine

ADDRESS: University of Texas Medical School
Division of Rheumatology
6431 Fannin, MSB 5.270
Houston, Texas 77030
Phone: 713-500-6900
FAX: 713-500-0580
Email: john.d.reveille@uth.tmc.edu

CITIZENSHIP: USA

UNDERGRADUATE EDUCATION:

1969-1970 St. John Vianney Minor Seminary, Miami, FL
1970-1971 Miami-Dade Junior College, Associate of Arts
1971-1973 University of Florida, Bachelor of Science, Chemistry

GRADUATE EDUCATION:

1973-1977 Johns Hopkins University, School of Medicine, Doctor of Medicine

POSTGRADUATE TRAINING:

1977-1978 Intern, University of Miami Affiliated Hospitals
1978-1980 Resident in Medicine, University of Miami
1980-1983 Fellow-Rheumatology, Johns Hopkins University School of Medicine

ACADEMIC APPOINTMENTS:

1983-1987 Assistant Professor of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham School of Medicine Birmingham, Alabama
1987-1990 Assistant Professor of Medicine, Division of Rheumatology and Clinical Immunogenetics, The University of Texas Medical School at Houston, Texas
1990-1997 Associate Professor of Medicine (with tenure), Division of Rheumatology and Clinical Immunogenetics, The University of Texas Medical School at Houston Houston, Texas
1995-2007 Faculty Member, Graduate School of Biomedical Sciences, The University of Texas-Houston Health Science Center
1997-Present George S. Bruce, Jr. Professor in Arthritis and Other Rheumatic Diseases, Division of Rheumatology and Clinical Immunogenetics, The University of Texas-Houston Health Science Center
1997-2006 Clinical Director, NIH Specialized Center of Research in Scleroderma
5/02-present Director, Division of Rheumatology and Clinical Immunogenetics, The University of Texas-Houston Health Science Center
5/02-present Chief, Division of Rheumatology, Memorial-Hermann Hospital

5/03-8/05 Fellowship Training Program Director, Division of Rheumatology and
Clinical Immunogenetics, The University of Texas-Houston Health
Science Center

HOSPITAL APPOINTMENTS:

1981-83 Attending Physician, Sinai Hospital of Baltimore
1983-1988 Physician, The University of Alabama Affiliated Hospitals
1987 - present Memorial-Hermann Hospital
1990 - present Harris County Hospital District
1991-present Director, Harris County HIV-Rheumatology Clinic (Thomas Street Clinic)
2002-present Medical Staff, St. Luke's Hospital, Houston, TX
2005-present Adjunct Professor of Medicine, M.D. Anderson Cancer Center

LICENSURE:

Florida-ME32977-8/2/78-12/31/89
Maryland-G25204-7/17/80-9/30/83
Alabama-11051-7/27/83-12/31/87
Texas-H3153-7/20/87-present

CERTIFICATION:

1980 Diplomate, American Board of Internal Medicine
1982 Diplomate, American Board of Internal Medicine, Subspeciality of
Rheumatology

PROFESSIONAL ORGANIZATIONS (AND COMMITTEES OF THESE):

1983 - present Fellow, American College of Rheumatology (formerly American Rheumatism
Association)
1978 - 1986 American Medical Association
1984 - 1994 American Federation for Clinical Research
1984 - 1986 Founder, Alabama Society for the Rheumatic Diseases
1987 - 2000 SLE Study Group, American College of Rheumatology
1987 - 2007 Member, Medical Advisory Board, Spondylitis Association of America
1993-1995 Chairman, Medical Advisory Board, Spondylitis Association of America
1989 - 2004 Member, American Society for Histocompatibility and Immunogenetics
1991 - present Member, Baylor Center for AIDS Research
1999-2004 Director, The North American Spondylitis Consortium
2000-2002 Co-Chair, Spondyloarthropathy Component, The XIII International
Histocompatibility Workshop
2002-present Member, Assessments in Ankylosing Spondylitis (ASAS) Working Group
2003-2004 Co-Chairman, Spondyloarthritis Research and Treatment Network
(SPARTAN)
2002-2006 Member, Scientific Advisory Committee, PANLAR meetings 2006
2004-2006 Vice-Chairman, Spondyloarthritis Research and Treatment Network
(SPARTAN)
2004-present Member, Finance Committee, American College of Rheumatology

2005-present	American College of Rheumatology (ACR) Official Liason to the Pan American League Against Rheumatism (PANLAR)
2006-present	Secretary, Spondyloarthritis Research and Treatment Network (SPARTAN)
2007-present	Member, Board of Directors, Spondylitis Association of America
2008-present	Member, Advisory Board, ASAS Working Group
2008-present	Treasurer, Pan American League Against Rheumatism (PANLAR)

HONORS AND AWARDS:

1981	Merck, Sharpe and Dohme Travel Scholarship Award
1983	Merck, Sharpe and Dohme Senior Fellow Award
1985	Lupus Foundation of America Grant - \$10,000
1986	E.J. Dubois Memorial Award for Research in Systemic Lupus Erythematosus, Presented at the American Rheumatism Association Meetings in New Orleans
1986	V.A. Merit Review Award - (declined)
1988 - 1991	Hulda Irene Duggan Arthritis Investigator of the Arthritis Foundation
1988 - 1993	N.I.H. First Award
1990	ASHI Scholar Award - American Society For Histocompatibility and Immunogenetics 16th Annual Mtg
1990 - 1995	Dean's Teaching Excellence Award
1996	Outstanding Medical Service Award, Thomas Street Clinic
1997	Recognized Honoree @ Faculty Honors Convocation, The University of Texas Houston Medical School
1997	Alfred and Anna Brohn Memorial Award for Service to the Lupus Foundation of America.
1998	Elected to Alpha Omega Alpha Honor Medical Society, Delta Chapter
1998	Dean's Teaching Excellence Award
9/2003	Pfizer Visiting Professor in Rheumatology, The University of Tennessee at Memphis
2/2004	The William K. Ishmael Lectureship in Rheumatology, the Oklahoma Medical Research Foundation
4/2004	Kochman Visiting Professor for the Division of Rheumatology & Clinical Immunology at University of Maryland Baltimore.
10/2004	Honoree, Lupus Foundation of America, Gulf Coast Chapter
10/2004	Recognized Honoree @ Faculty Honors Convocation, The University of Texas Houston Medical School
08/05	Named to list of Texas "Super Docs 2005" in <i>Texas Monthly</i>
08/06	Named to list of Texas "Super Docs 2006" in <i>Texas Monthly</i>
08/07	Named to list of Texas "Super Docs 2007" in <i>Texas Monthly</i>

EDITORIAL POSITIONS:

1989 –1994	Editorial Board, <u>Arthritis & Rheumatism</u>
1998-2002	Editorial Board, <u>Rheumatology Index and Reviews</u>
1999-present	Editorial Board, Revista de La Asociacion Peruana de Reumatologia Reviewer: Arthritis Care and Research

Arthritis and Rheumatism
 Journal of Clinical Investigation
 The Journal of Rheumatology
 Tissue Antigens
 Journal of Immunology
 American Journal of Medicine
 Clinical Immunology and Immunopathology
 Annals of Internal Medicine
 The AIDS Reader

STUDY SECTIONS:

2007- Standing Member, Arthritis, Connective Tissue and Skin Diseases (ACTS)
 Study Section (NIAMS)
 1987-2007 Ad Hoc Reviewer for NIAMS, ACTS
 1988, 2003 Ad Hoc Reviewer for NIAID
 2006 Ad Hoc Reviewer for NHLBI
 2007 Ad Hoc Reviewer for Mammalian Genetics
 1991, 1998 ACR Abstract Selection Committee, SLE-Etiology and Pathogenesis
 1992, 1993, 2002-06 ACR Abstract Selection Committee, Spondyloarthropathies. etc
 1992, 1999, 2000 Site Visit Reviewer for NIH-NCRR
 1989 Arthritis Foundation
 1992-95; 2001-2003 Scleroderma Foundation
 1994 Lupus Foundation of America
 2003 Abbott Scholar Award reviewer.

MEDICAL SCHOOL COMMITTEES

1985-1986 Intern Selection Committee, Department of Medicine, The University of
 Alabama at Birmingham
 1990-2002 Scientific Advisory Committee, University Clinical Research Center, UTH-HSC
 1999-2006 Faculty Evaluation Committee, Department of Medicine, UTH-HSC
 2002-2005 LCME Educational Resources Committee, UTH-HSC
 2003-2005 Graduate Medical Education Committee, UTH-HSC
 2004-2010 Faculty Promotion and Tenure Committee, UTH-HSC School of Medicine
 2005-2006 Chairman, Faculty Evaluation Committee, Department of Medicine
 2005-present Faculty Promotion and Tenure Committee, Department of Medicine
 2006-2008 Research Committee, UTH-HSC School of Medicine

SERVICE TO THE COMMUNITY:

1987-Present Medical Advisory Board, Spondylitis Association of America
 1990-1995 Medical Advisory Board, Houston Center for Clinical Research
 1990 - 1997 Member, Board of Directors, Lupus Foundation of America, Houston Chapter
 1990 - 1995 Chairman, Medical Advisory Board, Lupus Foundation of America, Houston
 Chapter

1987 - 1997 Member, Medical Advisory Board, Lupus Foundation of America, Houston Chapter
1984 - 1987 Medical Advisory Board, Lupus Foundation of America, Birmingham Chapter
1993-1995 Chairman, Medical Advisory Board, Spondylitis Association of America
1995 - 2003 Member, Medical Advisory Board - Research, Initiating Treatment Action, , Houston, Texas

GRANT SUPPORT

Grants as P.I.-finished

1. Lupus Foundation of America Grant - 1985 \$10,000
RFLPs of the MHC Class II Region in Susceptibility to Systemic Lupus Erythematosus.
Role: PI
The major goals of this project are collect genomic DNA from 200 patients meeting ACR criteria for SLE to study restriction fragment length polymorphisms (RFLPs) of HLA-DR and DQ genes.
2. V.A. Merit Review Award - (declined)-1986 \$300,000
Characterization of a 9.2 kb PvuII Restriction Fragment Length Polymorphism in Ankylosing Spondylitis Susceptibility
Role: P.I.
The major goal of this project is to confirm the association of ankylosing spondylitis with a 9.2 kb PvuII RFLP that we have observed in Caucasian Alabama AS patients. This will include confirmation in other cohorts, including non-Caucasians, as well as characterization of the RFLP itself. We will isolate the potential disease-relevant gene within the fragment (by sequencing) and looking in genetic regions adjacent to the RFLP.
3. R29-AR39325-N.I.H. First Award-4/1/88-3/31/93 40%
Characterization of a 9.2 kb PvuII Restriction Fragment Length Polymorphism in Ankylosing Spondylitis Susceptibility
Role: P.I.
The major goal of this project is to confirm the association of ankylosing spondylitis with a 9.2 kb PvuII RFLP that we have observed in Caucasian Alabama AS patients. This will include confirmation in other cohorts, including non-Caucasians, as well as characterization of the RFLP itself. This will include isolation of a potential disease-relevant gene within the fragment (by sequencing) and looking in genetic regions adjacent to the RFLP.
4. Hulda Duggans Arthritis Foundation Investigator Award-9/1/88-8/31/01
Genetic Studies on Ankylosing Spondylitis Susceptibility.
Role: P.I.
The major goal of this project is to evaluate the MHC contribution to AS susceptibility, including to confirm the association of ankylosing spondylitis with a 9.2 kb PvuII RFLP that we have observed in Caucasian Alabama AS patients. This will include confirmation in other cohorts, including non-Caucasians, as well as

characterization of the RFLP itself. We will a potential disease-relevant gene within the fragment (by sequencing) and looking in genetic regions adjacent to the RFLP, as well as conducting HLA-DRB1, DQA1 and DQB1 typing by DNA methods.

5. Gulf Coast Regional Blood Center-1993-\$60,000

An Alternative Approach to HLA-A, -B, and -C Typing by DNA Methodology

Role: P.I.

We will examine HLA-A, -B and -C polymorphism by oligotyping using sequence specific oligonucleotide probes in local Caucasian, African American and Hispanic rheumatic disease patients and controls.

6. 5 R01 AR046208 (Reveille)7/1/99-6/30/04 30%

NIH \$4,519,825

Family Studies of the Genetics of Ankylosing Spondylitis

Role: PI

The major goals of this project are to collect 400 sib pairs from families with two or more sibs concordant for Ankylosing Spondylitis from 10 medical centers around the United States and Canada and the Spondylitis Association of America (the North American Spondylitis Consortium or NASC) to determine the relative impact of MHC versus non-MHC genes in predisposition to AS. This will involve carrying out at least one genome-wide scan and fine-mapping and candidate gene analyses.

Grants as PI-current

1. 1P01-052915-01- (Reveille) 7/1/06-6/30/11 30%

NIH \$5,660,936

Genetics and Ankylosing Spondylitis Pathogenesis

Role: PI

The major goals of this project are to conduct a genomewide association study of 505,000 SNPs on 1000 U.K. A.S. patients and 3000 U.K. controls and then to confirm the most highly associated 1-2% in 1500 U.S. AS patients and 1500 controls. These SNPS will then be applied to outcome in a prospective longitudinal studies of genetic versus nongenetic factors in AS prognosis. The spectrum of SpA will be examined in the first degree relatives of the AS patients and network modeling will be applied to genetic versus non genetic determinants of AS and SpA susceptibility and severity in AS patients and their relatives

2. 1T32AR052283-01 (Reveille) 4/1/07-3/31/12 5%

NIH \$1,553,195

Pre and Postdoctoral Training in the Rheumatic Diseases

Role: PI

Grants as Co-PI-finished

1. 5 RO1 AR042503 (Alarcon) 9/30/93-8/31/03 20%

NIH \$1,242,197
Outcome of SLE in Minorities-Nature vs. Nurture
Role: PI UTHSC-H Site

The major goal of this project are to determine the relative impacts of genetic versus sociodemographic, behavioral and immunologic factors in the outcome of systemic lupus erythematosus in three ethnic groups.

2. 1 P50 AR44888, Core B, SCOR in Scleroderma (Arnett) 9/01/97-8/31/06
5%

NIH/NIAMS \$640,687
Administrative and Financial Core
Role: PI of Core B

The major goals of this project are to determine the genetic factors involved in the pathogenesis of systemic sclerosis.

3. 1 R01 EY013139 (Martin) 4/1/01-3/31/04
3%

NIH \$139,695
Analysis of Genetic Susceptibility to Anterior Uveitis
Role: PI UTHSC-H Site

The major goals of this project are collect families with acute anterior uveitis (AAU) for eventual genome-wide scanning. Our role is to assist in the identification of such families from the NASC project above and to perform HLA class I and II typing on all family members.

4. 7 RO1 AR048465 (Ward) 9/1/01-8/31/06
5%

NIH \$300,000
Genetic Determinants of Ankylosing Spondylitis Severity
Role: PI UTHSC-H Site

The major goals of this project are collect 400 patients with Ankylosing Spondylitis (AS) of > 20 years duration for a cross-sectional study examining MHC and non-MHC genes and validated radiographic determinants of severity (BASRI) as well as 200 patients with AS of <20 years duration who will be followed prospectively for 2 years in order to determine genetic predictors of disease severity.

5. 1 P50 AR045231; Project 4 (Kimberly) 7/1/98-6/30/02
5%

NIH/NIAMS \$44,358
Specialized Center of Research in SLE
Role: PI UTHSC-H Site

The major goals of this project are to enroll patients with SLE of < 10 years duration from three ethnic groups to determine profiles of disease subsets of SLE (renal disease, etc) (the PROFILE study). These studies will be enhanced by the concomitant

collection of age, sex, ethnicity and locale matched controls (the CASSLE study) as well as available parents (the TRIO study).

6. 5 U24 AI49213, Project 3 (Hansen) 9/1/00-8/31/05

3%

NIH/NIAID \$12,665

HLA and Disease

Role: PI UTHSC-H Site

Dr. Reveille is the P.I. of the spondyloarthropathy component of this study to collect families from around the world with AS to determine impacts of HLA genes on susceptibility to spondyloarthropathy from different ethnic groups.

7. Centocor C0167T51 (Centocor Laboratories)

5/1/03-4/30/05 \$60,840

A Phase III Study of Infliximab in Ankylosing Spondylitis

This is a two year phase III trial of the efficacy and safety of infliximab in ankylosing spondylitis. Dr. Reveille's role is to oversee the three patients enrolled in the trial from UT-H

Grants as co-PI-current

1. a. 5 RO1 NS050627 (Brey)

4/01/07-3/31/11

1.4 calendar months

Neurocognitive Function in SLE

The major goal of this project were to determine the relative impacts of genetic versus sociodemographic and immunologic factors on cognitive functioning in systemic lupus erythematosus in three ethnic groups.

2. 6H12HA000390-09 3/1/1998 – 2/28/2008

1.2 calendar months

Department of Health and Human Services

RYAN WHITE TITLE I (DHHS) - RHEUMATOLOGY SERVICES

The major goal of this federal flow-through, fee-for service project is to provide an outpatient Rheumatology clinic for HIV positive individuals

3. 1 P50 AR44888- NIH/NIAMS

P50AR054144-02 (Arnett PI)

9/1/2006 – 8/31/201 0.60 calendar months

NIH/NIAMS Center for Research Translation in Scleroderma \$879,385.000

The major goal of this project is to improve our understanding of the genetic factors involved in the pathogenesis of systemic sclerosis.

4. R01 EY013139-04 (T.Martin, P.I.)

\$7/1/05-6/30/10 0.4 calendar months

Our role on this project will be to refer patients with acute anterior uveitis who themselves also have ankylosing spondylitis or who are first degree relatives thereof to Dr. Martin for phenotypic confirmation and immunologic studies. We will also perform extensive MHC genotyping (HLA-B, DRB1, DQA1, DQB1 and DPB1) of all patients and first degree relatives.

13. 1 P50 CA093459-01A1 (Project-5); (Dr. Jeffrey Lee) 7/1/04-12/31/08 0.60 calendar months

The major goal of this project is to determine the Genetic Basis Of Susceptibility To And Prognosis In Malignant Melanoma. Dr. Reveille's role is to oversee the HLA and other genetic analyses and to advise on other potential genetic markers.

5. M03-607 Abbott Laboratories

“A Phase III Study of Adalimumab in Ankylosing Spondylitis 4/1/04 – 3/31/10 0.60 calendar months

This is a two year phase III trial of the efficacy and safety of adalimumab in ankylosing spondylitis. Dr. Reveille's role is to oversee the five patients enrolled in the trial from UT-H

6. Centocor C0148T09 (Centocor Laboratories)

A Randomized, Double-blind Trial of the Efficacy of Golimumab in AS 0.5 calendar months
1/1/06 – 12/31/10

This is a five year multicenter phase II trial of the efficacy and safety of golimumab in ankylosing spondylitis. Dr. Reveille's role is to oversee the patients enrolled in the trial from UT-H.

ABSTRACTS

1. Reveille JD, Enlow RW, Bias WB, Winkelstein GA, Provost TT, Dorsch CA, Arnett FC: Studies of HLA genotypes, complement component deficiency and autoantibody relationships in familial SLE. Clin Res 30:662A, 1982.
2. Reveille JD, Boling E, Wilson R, Dorsch CA, Provost TT, Arnett FC: Familial occurrence of primary Sjögren's syndrome, other immune disorders and auto-antibodies in four kindreds: An HLA analysis. Arthritis Rheum 25:(suppl);S33,1982.
3. Reveille JD, Wilson R, Dorsch CA, Bias WB, Arnett FC: HLA genotypes and autoantibody expression in autoimmune families. Arthritis Rheum 25:(suppl); S134,1982.
4. Reveille JD, Bias WB, Hochberg MC, Arnett FC: Sacroiliitis in the Old Order Amish: Prevalence and absence of HLA associations. Arthritis Rheum 25:(suppl);S18, 1983.
5. Reveille JD, Bias WB, Hochberg MC, Arnett FC: Rheumatic disease and autoantibodies in the Old Order Amish. Prevalence and HLA associations. Arthritis Rheum 26: (suppl);S40, 1983.
6. Reveille JD, Wilson R, Bias WB, Provost T, Arnett FC: Familial SLE: Immunogenetic studies of HLA, Gm and autoantibodies in nine extended Caucasian kindreds. Arthritis Rheum 26:(suppl);S13, 1983.
7. Reveille JD, Arnett FC, Provost TT, Bias WB, McLean RH: Null alleles of the fourth component of complement (C4) in familial systemic lupus erythematosus (SLE), Clin Res 32:722A, 1984.
8. Bias WB, Meyers DA, Conley CL, Reveille JD, Wilson RW, Arnett FC: Evidence that autoimmunity is a Mendelian dominant trait. Am J Hum Genet 35:77A, 1983.
9. McDaniel DO, Reveille JD, Barger B, Acton RT: Association of a restriction fragment length polymorphism (RFLP) with seronegative spondyloarthropathies (SNSA). Biochemical Society Bulletin 7:126, 1985.
10. McDaniel DO, Reveille JD, Barger BO, Acton RT: Molecular basis for the association of HLA-B27 phenotype with seronegative spondyloarthropathies (SNSA). Hum

- Immunol 14:169, 1985.
11. Reveille JD and Alarcón GS: Survival in systemic lupus erythematosus (SLE). Demographic (DEMO), socioeconomic (SE) and clinical factors (CLIN). *Arthritis Rheum* 29:(Suppl);S39, 1986.
 12. Reveille JD, Waldo FB, Barger BO, Acton RT: Racial differences in HLA antigens in SLE patients. *Arthritis Rheum* 29:(Suppl);S70, 1986.
 13. Reveille JD, McDaniel DO, Barger BO, Koopman WJ, Acton RT: Restriction fragment length polymorphism (RFLP) in the seronegative spondyloarthropathies (SNSA). *Arthritis Rheum* 29:(suppl);S32, 1986.
 14. Reveille JD, McDaniel DO, Barger BO, Acton RT, Koopman WJ: Restriction fragment length polymorphism (RFLP) analysis in familial ankylosing spondylitis. Independent segregation of a 9.2 kb Pvu II RFLP from B27 haplotypes. *Arthritis Rheum* 30:(suppl); S36, 1987.
 15. Hagglund KJ, Haley WE, Alarcón GS, Reveille JD, Richards JS: The impact of psychological factors versus objective disease on rheumatoid arthritis patient outcome. *Arthritis Rheum* 30:(suppl);S62, 1987.
 16. Reveille JD, McDaniel DO, Barger BO, Koopman WJ, Acton RT: Restriction fragment length polymorphism (RFLP) in ankylosing spondylitis (AS): Association with a 9.2 kb Pvu II fragment. *Arthritis Rheum* 29:(suppl);S26, 1986.
 17. Reveille JD, and Alarcón GS: Survival in systemic lupus erythematosus (SLE): Demographic (DEMO), socioeconomic (SE), clinical factors (CLIN), and causes of death. *Arthritis Rheum* 29:(suppl);S27, 1986.
 18. Reveille JD, Barger BO, Acton RT: Demographic differences in the clinical presentation and immunogenetics of systemic lupus erythematosus (SLE). *Arthritis Rheum* 29: (suppl);S94, 1986.
 19. Summers MN, Haley WE, Alarcón GS, Reveille JD: The relationship of psychosocial variables to pain and functional disability associated with osteoarthritis (OA). *Arthritis Rheum* 29:(suppl);S146, 1986.
 20. Hagglund KJ, Haley WE, Richards JS, Alarcón GS, Reveille JD: Predicting individual differences in pain and functional impairment among rheumatoid arthritis patients. *Arthritis Rheum* 30:(suppl);S195, 1987.
 21. Reveille JD, McDaniel DO, Barger BO, Acton RT, Koopman WJ: Restriction fragment length polymorphism (RFLP) analysis in familial ankylosing spondylitis: Independent segregation of a 9.2 kb Pvu II RFLP from B27 haplotypes: *Arthritis Rheum* 30:(suppl); S36, 1987.
 22. Reveille JD, Phelps P, Acton RT, Koopman WJ, Barger BO, McDaniel DO: Restriction fragment length polymorphism (RFLP) analysis in the seronegative spondyloarthropathies: Independent segregation of a 9.2 kb Pvu II RFLP and B27 haplotypes. *Arthritis Rheum* 30:(suppl);S24, 1987.
 23. Straaton KV, Chatham WW, Smith SH, Reveille JD, Koopman WJ: Prevalence of clinically significant Libman-Sacks endocarditis (LSE) and valvulitis in SLE: A not uncommon problem. *Arthritis Rheum* 30:(suppl);S70, 1987.
 24. Goldstein R, Olsen ML, Arnett FC, Duvic M, Pollack MS, Reveille JD: Deletion of C4A genes in black Americans with systemic lupus erythematosus. *Arthritis Rheum* 31: (suppl);S22, 1988.
 25. Arnett FC, Hamilton RG, Reveille JD, Bias WB, Reichlin M, Harley JB: Genetic

- studies of Ro (SS-A) and La (SS-B) autoantibodies detected by ELISA in families with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (SS). *Arthritis Rheum* 31: (suppl):S20, 1988.
26. Tomana M, Schrohenloher RE, Reveille JD, Bias W, Arnett FC, Koopman WJ: Evidence for a familial defect in galactosylation of IgG in systemic lupus erythematosus (SLE). *Arthritis Rheum* 31:(suppl);S55, 1988.
 27. McMenemy AM, Reveille JD: HLA-C allele typing by restriction fragment length polymorphism (RFLP) analysis in psoriatic arthritis. *Arthritis Rheum* 39:(suppl);S95, 1988.
 28. Reveille JD, Hamilton RG, Arnett FC: Analysis of HLA-DR and DQ subtypes associated with the Ro(SS-A) and La (Ss-B) autoantibodies. *Hum Immunol* 23:139, 1988.
 29. Reveille JD, Schrohenloher RS, Acton RT, Barger BO: Restriction fragment length polymorphism (RFLP) analysis of class II MCH genes in SLE: associations with clinical and autoantibody subsets in Caucasians. *Hum Immunol* 23:138, 1988.
 30. Reveille JD, Acton RT, Barger BO: Restriction fragment length polymorphism (RFLP) analysis of class II MHC genes in SLE: Lack of disease association in American blacks. *Hum Immunol* 23:138, 1988.
 31. Olsen M, Goldstein R, Arnett FC, Duvic M, Pollack M, Reveille JD: C4A gene deletion and HLA associations in black Americans with systemic lupus erythematosus (SLE). *Hum Immunol* 23:128, 1988.
 32. Isern RA, Arnett FC, Duvic M, Reveille JD, Erlich H: Analysis of polymerase chain reaction (PCR) amplified DR ϵ 3 genes (DRw52) with allele specific oligonucleotide probes (ASO) in patients with myositis and Sjögren's syndrome (SS). *Arthritis Rheum* 32:(suppl);S82, 1989.
 33. Barron KS, Joseph AK, MacLeod MJ, Duvic M, Reveille JD: Restriction fragment length polymorphism (RFLP) analysis of class II MHC in pauciarticular juvenile rheumatoid arthritis. *Arthritis Rheum* 32:(suppl);S83, 1989.
 34. Reveille JD, MacLeod MJ, Whittington K, Arnett FC: "Trans" or "Cis" combinations of HLA-DQ \forall 2 or \forall 6/DQ \exists 2 or \exists 6 chain genes promote the Ro (SS-A)/ La (SS-B) autoantibody responses. *Hum Immunol* 21:(suppl);S54, 1989.
 35. Barron KS, Joseph AK, MacLeod MJ, Reveille JD: Analysis of restriction fragment length polymorphism of class II MHC in pauciarticular juvenile rheumatoid arthritis. *Hum Immunol* 21:(suppl);S56, 1989.
 36. Reveille JD, MacLeod MJ, Arnett FC: HLA-DQ and not DP or DR genes are most specifically associated with the Ro(SS-A) and La(SS-B) autoantibody responses. *Clin Res* 38:277A, 1990.
 37. Reveille JD, Duvic M: Peripheral arthritis and HLA antigens in HIV-associated psoriasis. *Clin Res* 38:580A, 1990.
 38. Barron KS, Owerbach D, Cain L, Brown T, Reveille JD: HLA-DR and DQ DNA polymorphism in polyarticular juvenile rheumatoid arthritis, *Arthritis Rheum* 33: (suppl);S32, 1990.
 39. Isern R, Arnett FC, Goldstein R, Anderson K, Durban E, Owerbach D, Reveille JD: Anti-centromere antibodies (ACA) are associated with DRB1 third hypervariable sequences shared by HLA-DR1 and DR4. *Arthritis Rheum* 33:(suppl);S32, 1990.
 40. McMenemy A, Reveille J: MHC-Class II heterozygosity by restriction fragment length

- polymorphism (RFLP) and polymerase chain reaction (PCR) in psoriatic arthritis. *Arthritis Rheum* 33:(suppl);S68, 1990.
41. Barron K, MacLeod M, Cain L, Joseph A, Reveille J: HLA DPw2.1 constitutes an independent risk factor in susceptibility to pauci articular juvenile rheumatoid arthritis (Pa JRA). *Arthritis Rheum* 33:(suppl);S92, 1990.
 42. Reveille JD, MacLeod MJ, Arnett FC: The Ro/La autoantibody response in localized to the second hypervariable region of HLA-DQ \forall and \exists outermost domains. *Arthritis Rheum* 33:(suppl); S99, 1990.
 43. Olsen ML, Arnett FC, Reveille JD: Anti-Sm and Anti-RNP antibodies are associated with distinct and different HLA-DQ \forall and \exists chain genes. *Arthritis Rheum* 33:(suppl); S100, 1990.
 44. Arnett FC, Anderson KL, Olsen ML, Moulds JM, Reveille JD: The lupus anticoagulant: Another autoantibody subset associated with HLA-DQ *Arthritis Rheum* 33:(suppl); S100, 1990.
 45. Reveille JD, Duvic M: Peripheral arthritis and HLA Antigens in HIV-Associated psoriasis. *Arthritis Rheum* 33:(suppl);S160, 1990.
 46. Reveille JD, Olsen ML, Arnett FC: Systemic Lupus Erythematosus (SLE): A composite disease of HLA-DQ associated Autoantibody responses. *Human Immunol* 22:(suppl); 40;1990.
 47. Figueroa K, Arnett FC, Targoff IN, Reveille JD: Association of HLA-DPB1*0101 with autoantibodies in Caucasians with myositis. *Clin Res* 38:974A, 1990.
 48. Khanduja S, Arnett FC, Reveille JD: HLA-DQ beta genes encode and epitope for lupus specific DNA antibodies. *Clin Res* 38:975A, 1990.
 49. Reveille JD, Arnett FC, Buyon J: The association of HLA-DR3, DQw2.1 with anti-Ro/La primarily reflects reactivity against anti-48kd La protein. *Arthritis Rheum* 34:(suppl);S138, 1991.
 50. Reveille JD, Moreda R, Goldstein R, Durban E, Arnett FC: The molecular genetics of the anti-topoisomerase (TOPO) response in systemic sclerosis: association with an epitope in the third hypervariable region of the HLA-DQB1 first domain. *Arthritis Rheum* 34:(suppl);S138, 1991.
 51. Reveille JD, Bias WB, MacLeod MJ, Small D, Arnett FC: The molecular genetics of systemic lupus erythematosus (SLE) in Mexican Americans. *Arthritis Rheum* 34:(suppl);S138, 1991.
 52. Reveille JD, Moreda R, Goldstein R, Durban E, Arnett FC: Demographic differences in autoantibodies and HLA Class II alleles in scleroderma (systemic sclerosis). *Arthritis Rheum* 34:(Suppl);S57, 1991.
 53. Barron KS, Silverman ED, Gonzales JC, MacLeod M, Anderson K, Reveille JD: MHC class II alleles in Kawasaki syndrome (KS) - lack of significant correlation with disease or cardiac involvement. *Arthritis Rheum* 34: (suppl);S121, 1991.
 54. Barron K, Silverman E, Gonzales J, Whittington K, MacLeod M, Arnett F, Reveille J: Evidence for a role for HLA class II genotypes in age at systemic lupus erythematosus (SLE) onset. *Arthritis Rheum* 34: (suppl);S37, 1991.
 55. McCarty GA, Lister KA, Kendrick DG, Bias WB, Petri MA, Reveille JD, Arnett FC: Autoantibodies to cardiolipin (aCL) & to phosphatidyl serine (aPS) & HLA-DQ associations in Mexican-American & black patients (PTS) with systemic lupus erythematosus (SLE). *Arthritis Rheum* 34: (suppl); S139, 1991.

56. Reveille JD, Moreda R, Goldstein R, Durban E, Arnett FC: HLA class II genotypes in Caucasians with progressive systemic sclerosis (PSS): associations with autoantibody subsets. *Human Immunol* 32: (suppl); 97, 1991.
57. Howard R, Arnett F, Reveille J, Durban E, Hodge T, Cameron D, Weathers E, Paxton G: Clustering of scleroderma among Choctaw Native Americans. *Arthritis Rheum* 35: (suppl) S205, 1992.
58. Reveille JD, Arnett FC, Chan EKL, Buyon JP: Demographic, clinical and immunogenetic determinations in the anti-52 vs 60kdD RO/SSA autoantibody responses detected by ELISA. *Arthritis Rheum* 35: (suppl) S211, 1992.
59. Appleyard J, Ahearn JM, Taurog JD, Choo SY, Barron KS, Arnett FC, Reveille JD: HLA-B27 subtypes in patients with spondyloarthropathy. *Arthritis Rheum* 35: (suppl) S58, 1992.
60. Reveille JD, Targoff IN, Mimori T, Nguyen HC, Goldstein R, Arnett FC: MHC class II alleles associated with myositis. *Arthritis Rheum* 35: (suppl) S84, 1992.
61. Arnett FC, McCarty GA, Reveille JD: MHC class II alleles and antiphospholipid antibodies (APA). *Arthritis Rheum* 35: (suppl) S181, 1992.
62. Love LA, Burgess SH, Hill PC, Oddis CV, Medsger TA, Leff RL, Plotz PH, Reveille JD, Arnett FC, Targoff IN, Miller FW: Geographical and seasonal clustering in the onset of idiopathic inflammatory myopathy (IIM) in groups defined by myositis-specific autoantibodies (MSA). *Arthritis Rheum* 35: (suppl) S40, 1992.
63. Buyon JP, Slade S, Reveille J, Chan EKL: Dissecting the anti-52kD Ro response in complete heart block (CHB). *Arthritis Rheum* 35: (suppl) S69, 1992.
64. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcón GS: Anticardiolipin antibodies (ACLA) negatively impact on survival in systemic lupus erythematosus (SLE). *Arthritis Rheum* 35: (suppl) S156, 1992.
65. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcón GS: Lack of association between anticardiolipin antibodies (ACLA), HLA and SLE. *Arthritis Rheum* 35: (suppl) S157, 1992.
66. Reveille JD, Burgard SL, Gulko PS, Alarcón: Frequency distribution of DPB1 specificities among SLE patients with or without anticardiolipin antibodies. *Arthritis Rheum* 36: (5); (suppl) S30, 1993.
67. Reveille JD, Appleyard J, Ahearn JM, Lam JL, Taurog JD, Arnett FC: HLA-B27 subtypes and spondyloarthropathy in three different racial groups: Disease predisposition appears to be linked to the broad HLA-B27 specificity. *Clin Res* 41:245A, 1993.
68. Krylov M, Reveille JD, Alexeeva L, Erdesz S, Arnett FC: HLA-B27 subtypes and class II alleles among the Chukotka native Siberians. *Arthritis Rheum* 36 (suppl) A223, 1993.
69. Reveille JD, Arnett FC, Acock K, Goldstein R, Fritzler M: MHC class II alleles and anti-CENP antibodies in scleroderma. *Arthritis Rheum* 36 (suppl) B245, 1993.
70. Moulds JM, Smith Evans, Warner NB, Reveille JD, Arnett FC: Complement receptor one (CR1) size variation in systemic lupus erythematosus patients. *Arthritis Rheum* 36 (suppl) C53, 1993.
71. Kazi S, Cohen PR, Reveille JD: Clinical and immunogenetic features of the diffuse infiltrative lymphocytosis syndrome (DILS) in a large outpatient population from the Southern U.S. *Arthritis Rheum* 36 (suppl) 172, 1993.

72. Barron KS, Deulofeut H, Reveille JD, Robinson MA: T Cell receptor (TCR) V β null alleles in juvenile rheumatoid arthritis (JRA). *Arthritis Rheum* 36 (suppl) 263, 1993.
73. Barron KS, Carrington M, Reveille JD, Robinson MA: Polymorphism in tap genes in Reiter's Syndrome. *Arthritis Rheum* 36 (suppl) A225, 1993.
74. Reveille JD: HLA class II alleles in Caucasians with Reiter's Syndrome. *Arthritis Rheum* 36 (suppl) A226, 1993.
75. Arnett FC, Reveille JD, Elkon KB: Autoantibodies to ribosomal P in systemic lupus erythematosus (SLE): Clinical, ethnic, and immunogenetic associations. *Arthritis Rheum* 37 (suppl 9) S167:54, 1994.
76. McDaniel O, Reveille JD, Pratt PW, Alarcón GS: Seropositivity, but not the "Rheumatoid Epitope", predicts disease severity in African-American (Af-Am) RA patients. *Arthritis Rheum* 37 (suppl 9) S169:63, 1994.
77. McDaniel O, Reveille JD, Pratt PW, Alarcón GS: The large majority of African-American (Af-Am) patients with seropositive RA do not possess the "Rheumatoid Epitope". *Arthritis Rheum* 37 (suppl 9) S169:64, 1994.
78. Perl A, Colombo E, Daitt, Poiesy BJ, Phillips PE, Reveille JD, Arnett FC: Correlation of HRES-1 and U1snRNP antibodies in patients with systemic lupus erythematosus and overlap syndromes - A comprehensive study of antinuclear antibodies and HLA Class II alleles. *Arthritis Rheum* 37 (suppl 9) S215:337, 1994.
79. Calvo-Alen J, Bastian H, Straaton KV, Singh K, Mikhail I, Rodriguez J, Friedman A, Reveille JD, Alarcón GS: Use of the systemic lupus activity measure (SLAM) items and global: result of a training process. *Arthritis Rheum* 37 (suppl 9) S218:354, 1994
80. Kazi S, Miller SM, Reveille JD: Causes of elevated serum creatine kinase in a large outpatient population infected with HIV-1. *Arthritis Rheum* 37 (suppl 9) S234:447, 1994.
81. Arnett FC, Reveille JD, Goldstein R, Pollard KM, Fritzler MJ: Autoantibodies to U3-RNP (Febrillarin) in systemic sclerosis (SSc): Frequencies and immunogenetic studies. *Arthritis Rheum* 37 (suppl 9) S261:610, 1994.
82. Tan FK, Howard RF, Reveille JD, Moulds JM, Paxton G, Arnett FC: Case control study of systemic sclerosis among Choctaw Native Americans in Southeastern Oklahoma. *Arthritis Rheum* 37 (suppl 9) S282:735, 1994.
83. Colombo E, Mark K, Agarwal RK, Reveille JD, Arnett FC, Phillips PE, Perl A: Human endogenous retroviral protein HRES-1 P28 may be the primary target of RNP autoantibodies: Mapping of crossreactive epitopes with synthetic peptides and recombinant protein. *Arthritis Rheum* 37 (suppl 9) S315:928, 1994.
84. Sharma A, Baethge B, Reveille JD, Vaidya S, Lisse J: Human leukocyte antigen (HLA)-DR Haplotypes in Rheumatoid Arthritis (RA)/polymyositis (PM) overlap: No association with DRB₁04. *Arthritis Rheum* 37 (suppl 9) S333:1031, 1994.
85. Reveille JD, Alarcón GS, Fowler S, Pillemer S, Neuner R, Clegg DO, Trentham D, Leisen J, Cooper S, Duncan H, Mikhail I, Tuttleman M, Heyse S, Tilley B: Lack of a gene-dose effect for the "Rheumatoid" epitope in RA patients from a large multicenter clinical trial. *Arthritis Rheum* 37 (suppl 9) S359:1190, 1994.
86. Day HM, Reveille JD, Whittington KF, Thiagarajan P, Arnett FC: Clinical, ethnic and immunogenetic correlations with anti- β 21 glycoprotein (anti- β 2GP) anti-cardiolipin and lupus anticoagulant in patients with the antiphospholipid antibody syndrome (APS). *Arthritis Rheum (Suppl)* 38: (9); 1995.

88. Zonana-Nacach A, Alarcón GS, Reveille JD, Taiana-Alexander M, Alexander RW, Bradley LA, Ball GV: Do antinuclear (ANA) positive fibromyagia (FM) patients differ from anegative FM patients? *Arthritis Rheum (suppl)* 38: (9); 1995.
89. Mikhail OS, Cook N, Singh K, Straaton KV, Reveille JD, Friedman A, Moulds JM, Roseman J, Go RCP, Bartolucci A, Alarcón GS: Discrepant perception of disease activity among patients with SLE from three different ethnic groups. *Arthritis Rheum (Suppl.)* 38: Nov. 9, 1995.
90. Friedman AW, Straaton KV, Burst N, Roseman J, Reveille JD, Alarcón GS: Predictors of self-reported outcome in a large prospective SLE cohort study. *Arthritis Rheum (suppl)* 39: (9); 1996.
91. Ahmed SS, Arnett FC, Smith CA, Ahn C, Reveille JD: HLA-DRB1 alleles predict the development of methotrexate-associated accelerated nodulosis syndromes. *Arthritis Rheum (suppl)* 39: (9); 1996.
92. Reveille JD, Moulds JM, Ahn C, Friedman A, Lisse J, Straaton K, Alarcón GS: The effect of HLA-class II, C4 and CR1 alleles and ethnicity on the onset of systemic lupus erythematosus (SLE). *Arthritis Rheum (suppl)* 39: (9); 1996.
93. Bastian HM, Alarcón GS, Roseman J, Straaton KV, Burst N, Lisse J, Friedman A, Moulds JM, Reveille JD: HLA-DQB1 alleles as predictors of lupus nephritis among Caucasian (C), Hispanic (H), and African America (AA) patients. *Arthritis Rheum (suppl)* 39: (9); 1996.
94. Alarcón GS, Straaton KV, Roseman J, Burst N, Lisse J, Moulds JM, Friedman AW, Reveille JD: Genetic and non-genetic factors as determinants of disease activity in Hispanic (H), African-American (AA), and Caucasian (C) patients. *Arthritis Rheum (suppl)* 39: (9); 1996.
95. Straaton KV, Alarcón GS, Roseman J, Burst N, Moulds JM, Lisse JR, Friedman AW, Reveille JD: Determinants of disease damage in Hispanic (H), African-American (AA) and Caucasian (C) SLE patients. *Arthritis Rheum (suppl)* 39: (9); 1996.
96. Zonana-Nacach A, Calvo-Alen J, Singh KP, Lisse JR, Mikhail I, Reveille JD, Alarcón GS, Fraga A: Damage in SLE among Hispanic patients from Mexico (MX), Texas (US) and Spain (SP). *Arthritis Rheum (suppl)* 39: (9); 1996.
97. Williams F, Husain R, Jumshyd J, Reveille JD: The prevalence of diffuse infiltrative lymphocytosis syndrome (DILS) and SICCA symptoms in HIV-1 positive outpatients. *Arthritis Rheum (suppl)* 39: (9); 1996.
98. Rodriguez J, Burst N, Reveille JD, Alarcón GS: The effect of acculturation on health-related attitudes, behavior and outcome in Hispanic SLE patients. *Arthritis Rheum (suppl)* 39: (9); 1996.
99. Mikhail IS, Roseman J, Burst N, Straaton K, Situ M, Reveille JD, Alarcón GS: Impact of social support, illness-related behavior, and learned helplessness on disease activity in patients with systemic lupus erythematosus (SLE). *Arthritis Rheum (suppl)* 39: (9); 1996.
100. Tan F, Stivers DN, Chakarabarty R, Pham H, Anderson K, Lupski J, Reveille JD, Howard R, Arnett FC: Microsatellite mapping of candidate genes for scleroderma in Choctaw native Americans. *Arthritis Rheum (suppl)* 39: (9); 1996.
101. Reveille JD, Fraser PA, Taurog JD, Pollack M, Ahearn JM, Khan MA, Appleyard J, Arnett FC: HLA-B27 subtypes in African Americans with spondyloarthritis (SpA). *Arthritis Rheum (suppl)* 39: (9); 1996.

102. Salmon JE, Ng S, Lisse J, Friedman A, Reveille JD, Alarcón GS: Allelic variants of FcyRIIA may contribute to the high prevalence of nephritis in Mexican American lupus. *Arthritis Rheum (suppl)* 40: (176);S60 1997.
103. Calvo A, Moulds J, Calvo F, Alarcón GS, Reveille JD: Systemic lupus erythematosus (SLE) in peruvian Mestizos: A clinical serologic and immunogenetic analysis. *Arthritis Rheum (suppl)* 40: (183);S61 1997.
104. Williams FM, Barron BJ, Lemki L, Lin HJ, Hollinger FB, Reveille JD: Short term moderate dose prednisone therapy in the diffuse infiltrative lymphocytosis syndrome (DILS): A prospective study. *Arthritis Rheum (suppl)* 40: (372);S92 1997.
105. Alarcón GS, Bartolucci AA, Roseman JM, Freidman AW, Straaton KV, Goel N, Burst NM, Reveille JD. Predictors of disease damage early in the course of SLE among patients from different ethnic groups. *Arthritis Rheum (suppl)* 40: (776);S160 1997.
106. Bastian HM, Mikhail I, Straaton KV, Friedman AW, Lisse JR, Burst N, Reveille JD, Alarcón GS. Factors associated with early death in African-American and Hispanic patients with SLE. *Arthritis Rheum (suppl)* 40: (777);S160 1997.
107. Bastian HM, Mikhail IS, Bradley L, Burst N, Reveille JD, Alarcón GS. Absence of renal disease but not ethnicity accounts for discrepant perception of disease activity among LUPUS patients from different ethnic groups. *Arthritis Rheum (suppl)* 40: (778);S160 1997.
108. Reveille JD, Spencer CH, Rivas-Chacon RF, Myones BL. HLA-DRB1, DQA1, and DPB1 alleles in children with juvenile arthritis from three ethnic groups. *Arthritis Rheum (suppl)* 40: (1263);S241 1997.
109. Wu J, Bansal V, Arnett F, Reveille J, Ginzler E, Gourley M, Ramsey-Golman R, Salmon J, Edberg J, Kimberly R. The FcyRIIA 176F/V polymorphism associates with the SLE phenotype in Caucasians and African Americans (AA). *Arthritis Rheum (suppl)* 40: (1709);S316 1997.
110. Calvo F, Bastian HM, McGwin G, Roseman J, Reveille JD, Lisse J, Alarcón GS. Predictor variables for early mortality in a prospective multiethnic cohort of SLE patients. *Arthritis Rheum (suppl)* 41: (429);S104 1998.
111. Richards JS, Alarcón GS, Roseman JM, McGwin G, Friedman AW, Baethge B, Reveille JD. Predictors of disease activity over time in SLE patients from three ethnic groups. *Arthritis Rheum (suppl)* 41: (430);S104 1998.
112. Bastian HM, Roseman JM, McGwin G, Reveille JD, Alarcón GS. Factors predictive of LUPUS nephritis (LN) in three ethnic groups. *Arthritis Rheum (suppl)* 41: (431);S104 1998.
113. Alarcón GS, Roseman JM, McGwin G, Friedman AW, Moulds JM, Lisse J, Richards JS, Straaton KV, Reveille JD. Predictors of damage early in SLE among patients from three ethnic groups. *Arthritis Rheum (suppl)* 41: S104 1998.
114. Kavanaugh A, Lahita R, Reveille J, Schur P, Sherrer Y, Solomon D. Evidenced-based guidelines or the use of antinuclear antibody testing. *Arthritis Rheum (suppl)* 41:S77, 1998.
115. Camargo-Coronel A, Calvo-Alen J, Zonana-Nacach A, Rodriguez-Valverde V, Ahn C, Alarcón GS, Reveille JD, Fraga A. Predictors of disease damage and activity among Hispanic and Spanish SLE patients. *Arthritis Rheum (suppl)* 41: S105 1998.
116. Calvo-Alen J, Rodriguez-Valverde V, Ahn C, Lisse J, Alarcón GS, Reveille JD. Predictors of disease damage and activity early in SLE among Spanish speaking

117. Zuniga R, Ng S, Reveille JD, Alarcón GS, Salmon JE. Allelic variants of FcyRIIIa and FcyRIIIa do not appear to be linked, but they both contribute to the risk for nephritis in Mexican American LUPUS. *Arthritis Rheum (suppl)* 41: S282 1998.
118. Reveille JD, Johnston KA, Ahn C, Tan FK, Friedman AW, Goel N, Moulds JM, McGwinn G, Roseman J, Alarcón GS. Genetic predictors of disease damage and activity early in SLE among patients from three ethnic groups. *Arthritis Rheum (suppl)* 41: S283 1998.
119. Brooks KT, Bastian HM, McGwin G, Roseman J, Bradley LA, Reveille JD, Lisse J, Calvo F, Alarcón GS. Different clinical manifestations are associated with patient over or under-estimation of disease activity in SLE in three ethnic groups. *Arthritis Rheum (suppl)* 41: S295 1998.
120. Aguilar MB, Williams FM, Cohen PR, Barron BO, Lamki L, Reveille JD. The effect of protease inhibitors on the presentation of the diffuse infiltrative lymphocytosis syndrome. *Arthritis Rheum* 42 (suppl): S333, 1999
121. Aguilar MB, Cho M, Reveille JD, Mayes MD, Arnett FC: Prevalences of familial systemic sclerosis and other autoimmune diseases in three U.S. cohorts. *Arthritis Rheum* 42(suppl): S186, 1999.
122. Friedman A, Fischbach M, Goel N, Aguilar M, Wan Y, Reveille J: Predictors of self-reported function in an multi-ethnic scleroderma cohort. *Arthritis Rheum* 42(suppl): S187, 1999.
123. Brooks KT, Gregory R, McGwin G, Chapman V, Roseman JM, Benavides G, Fessler B, Bastian HM, Lisse J, Reveille JD, Alarcón GS: A comparison between a vertical and a horizontal visual analog scale to measure disease activity for patients with SLE. *Arthritis Rheum* 42(suppl): S216, 1999.
124. Zonana-Nacach A, McGwin G, Morgan SI, Darnell B, Mikhail I, Reveille JD, Alarcón GS: Dietary intake in patients with systemic lupus erythematosus (SLE). *Arthritis Rheum* 42(suppl): S279, 1999.
125. Alarcón GS, McGwin G, Benavides G, Brooks K, Goel N, Rodriguez J, Friedman AW, Reveille JD: Poor acculturation into mainstream America does not contribute to disease activity among Hispanic SLE patients. *Arthritis Rheum* 42(suppl): S285, 1999.
126. Gregory R, Brooks KT, Fessler BJ, McGwin G, Bastian HM, Chapman V, Baethge B, Reveille JD, Friedman AW, Alarcón GS: Unexpected lack of occurrence of fibromyalgia among a cohort of SLE patients from three ethnic groups. *Arthritis Rheum* 42(suppl): S285, 1999.
127. Alarcón GS, McGwin G, Friedman A, Baethge BA, Reveille JD: Similarities and differences in baseline features predictive of disease activity in SLE patients of different ethnicities. *Arthritis Rheum* 42 (suppl): S288, 1999.
128. Alarcón GS, McGwinn G, Baethge BA, Reveille JD: Ethnic differences in damage accrual among Hispanic, African American and Caucasian SLE patients. *Arthritis Rheum* 42(suppl); S302, 1999.
129. Tan FK, Stivers DN, Reveille JD, Tsao BP, Arnett FC: Polymorphisms of the poly (ADP-ribose) polymerase gene (PARP) in African American systemic lupus erythematosus (SLE) patients. *Arthritis Rheum* 42 (suppl): S311, 1999.
130. Johnson R, Tan F, Arnett F, Ahn C, Reveille J: Single nucleotide polymorphism

- genotypes of matrix metalloproteinase-1 promoter in systemic sclerosis. *Arthritis Rheum* 43(Suppl):S262, 2000. (abstract).
131. Tew M, Tan F, Arnett F, Ahn C, Reveille J: Glutathione S-transferase genotypes in systemic sclerosis. *Arthritis Rheum* 43 (Suppl): S261, 2000 (abstract).
 132. Suarez-Almazor ME, Ahn C, Friedman AW, Fischbach MC, McNearney T, Lisse J, Reveille JD: Performance of outcomemasures in systemic sclerosis (SSc). *Arthritis Rheum* 43 (suppl): S319, 2000. (abstract).
 133. Reveille JD, Bruckel J, Inman R, Weisman M, Khan MA, Schumacher HR, Mahowald M, Stone M, Yu DTY, Akey J, Jin L. Genetic studies in familial ankylosing spondylitis. *Arthritis Rheum* 2000; 43 (suppl): S266.
 134. Lisse J, McNearney T, Baethge B, Goel N, Fischbach M, Friedman A, Ahn C, Reveille J: Digital ulceration in scleroderma (SSc): Independent risk factors early in the disease course in three racial groups from the GENISOS cohort. *Arthritis Rheum* 43 (suppl): S319, 2000.
 135. Fischbach M, McNearney T, Friedman A, Lisse J, Johnson R, Ahn C, Reveille J: Relationship of skin score with clinical, sociodemographic, serologic, and immunogenetic determinants in patients with scleroderma. *Arthritis Rheum* 43(Suppl):S320, 2000.
 136. Martin, T.M., T.M. Doyle, J.R. Smith, J.D. Reveille, J.T. Rosenbaum. Analysis of genetic susceptibility to anterior uveitis. *Ocular Immunol. Inflammation*. 2000; **8**:211.
 137. Tew MB, Arnett FC, Reveille JD, Tan FK: Mutations of Bone Morphogenic Protein Receptor 2 (BMP2) are not found in patients with pulmonary hypertension and connective tissue disorders. *Arthritis Rheum* 44(Suppl): S130, 2001.
 138. McNearney T, Fischback M, Friedman A, Johnson R, Ahn C, Reveille JD: The impact of sociodemographic (SD), behavioral/psychological (PSY), clinical (CLIN), autoantibodies (SER) and genetic (GEN) factors on therate of pulmonary deterioration in systemic sclerosis (SSc). *Arthritis Rheum* 44(Suppl): S131, 2001
 139. Suarez-Almazor ME, Ahn C, Friedman AW, Fischbach MC, McNearney T, Reveille JD. Working status in patients with early systemic sclerosis (SSc). *Arthritis Rheum* 2001; 44 (Suppl): S188.
 140. Fessler BJ, McGwin G, Alarcón GS, Roseman JM, Bastian HM, Friedman AW, Baethge BA, Reveille JD. Hydroxychloroquine (HCQ) usage is associated with decreased renal and cardiovascular damage in patients with SLE. *Arthritis Rheum* 2001; 44 (Suppl): S201.
 141. Reveille JD, Bruckel J, Inman R, Weisman M, Maksymowych W, Khan M, Mahowald M, Schumacher HR, Sawitzke A, Vasey F, Stone M, Yu A, Newman P, McClain J, Akey J, Jin L. Evidence for a second major histocompatibility complex gene in predisposition to familial ankylosing spondylitis (AS). *Arthritis Rheum* 2001; 44 (Suppl): S238.
 142. Tew MB, Tan FK, Kang SH, Friedman AW, Baethge BA, McGwin G, Fessler BJ, Bastian HM, Reveille JD, Alarcón GS. Mannose binding lectin (MBL) genetic polymorphisms do not significantly affect clinical manifestations of systemic lupus erythematosus (SLE). *Arthritis Rheum* 2001; 44 (Suppl): S251.
 143. Alarcón GS, McGwin G, Bastian HM, Fessler BJ, Friedman AW, Baethge BA, Reveille JD. Do the weighted criteria at diagnosis (TD) predict the rate of damage accrual in SLE. *Arthritis Rheum* 2001; 44 (Suppl): S246.

144. Martin, T.M., T.M. Doyle, J.R. Smith, J.D. Reveille, J. Bruckel, N.K. Wade, R.D. Levinson, J.T. Rosenbaum. Acute anterior uveitis in families. *Invest. Ophthalmol. Vis. Sci.* 2001; 42:S708.
145. Zhou X, Tan FK, Reveille JD, Wallis D, Milewicz DM, Ahn C, Wang A, Arnett FC: Functionally relevant single nucleotide polymorphisms in SPARC are associated with systemic sclerosis (scleroderma). *Arthritis Rheum* 46(suppl): S621, 2002
146. Reveille JD, Akey J, Bruckel J, Weisman MH, Inman RD, Stone M, Maksymowych WP, Schumacher HR, Khan MA, Mahowald ML, Sawitzke AD, Vasey F, Yu DTY, Jin L, Newman P, McClain JA. The Interleukin Receptor-1 Antagonist (IL1-Ra) gene is involved in predisposition to ankylosing spondylitis. *Arthritis Rheum* 46(suppl): S620, 2002
147. Tsui FWL, Tsui HW, Cheng EY, Stone MA, Payne U, Reveille JD, Shulman MJ, Paterson AD, Inman RD: A genetic marker in the 5' noncoding region of ankH is associated with ankylosing spondylitis. *Arthritis Rheum* 46(suppl): S620, 2002.
148. Maksymowych WP, Akey JM, Buenviaje H, O'Brien L, Jin L, Russell AS, Reveille: High throughput single nucleotide polymorphism (SNP) analysis of the interleukin-1 receptor antagonist (IL1Ra) in patients with ankylosing spondylitis by massARRAY matrix assisted laser desorption/ionization time of flight mass spectroscopy. *Arthritis Rheum* 46(suppl): S434, 2002
149. Khan MA, Akey J, Bruckel J, Weisman MH, Inman RD, Stone M, Maksymowych WP, Schumacher HR, Mahowald ML, Sawitzke AD, Vasey FB, Yu DTY, Jin L, Reveille JD: HLA-DRB1*0101 and DRB1*1501 but not HLA-B60 (B*4001) contribute to susceptibility to ankylosing spondylitis (AS). *Arthritis Rheum* 46(suppl): S435, 2002
150. Basu D, Williams FM, Kazi S, Ahn CW, Reveille JD: Factors affecting survival in patients with the Diffuse Infiltrative Lymphocytosis Syndrome (DILS). *Arthritis Rheum* 46(suppl): S67, 2002
151. Sanchez ML, McGwin G, Alarcón GS, Fessler B, Bastian HM, Baethge BA, Sandoval R, Friedman AW, Reveille JD: Factors predictive of poor compliance with study visits in longitudinal observational lupus studies. *Arthritis Rheum* 46(suppl): S239, 2002
152. Vilá LM, Alarcón GS, McGwin G, Friedman AW, Baethge BA, Bastian HM, Fessler B, Reveille JD: Variability of initial clinical manifestations and disease activity of systemic lupus erythematosus among four ethnic groups. *Arthritis Rheum* 46(suppl): S264, 2002.
153. Reveille JD, Akey J, Bruckel J, Weisman MH, Inman RD, Stone M, Maksymowych WP, Schumacher HR, Khan MA, Mahowald ML, Sawitzke AD, Vasey F, Yu DTY, Newman P, McClain JA, Jin L: Definite evidence for at least one other major histocompatibility complex (MHC) gene in addition to HLA-B27 in predisposition to ankylosing spondylitis. *Arthritis Rheum* 46(suppl): S392, 2002
154. Assassi S, Tercero GM, Reveille JD, Arnett FC, Mayes MD, McNearney T, Fischbach M, Tan FK: Polymorphisms of the endothelial nitric oxide synthase and angiotensin-converting enzyme show no association with systemic sclerosis. *Arthritis Rheum* 2003; 48 (suppl): S159.
155. Alarcón GS, McGwin G, Uribe A, Friedman AW, Roseman JM, Fessler BJ, Bastian HM, Baethge BA, Vilá LM, Reveille JD: Poor early self reported health-related quality

156. Uribe AG, Ho KT, Fessler BJ, Bastian HM, Reveille JD, Alarcón GS: Ethnicity does not predict compliance with clinic visits: Data from a multiethnic systemic lupus erythematosus cohort. *Arthritis Rheum* 2003; 48 (suppl): S187.
157. Uribe AG, Vilá LM, Sanchez ML, Reveille JD, Alarcón GS: Are the SLAM-R and the MEX-SLE-DAI adequate measures of disease activity in SLE? A comparative study among U.S. patients from different ethnicities. *Arthritis Rheum* 2003; 48 (suppl): S188.
158. Vilá LM, Alarcón GS, McGwin G, Friedman AW, Baegthe BA, Bastian HM, Fessler BJ, Reveille JD: Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual in systemic lupus erythematosus. *Arthritis Rheum* 2003; 48 (suppl): S188.
159. Fessler BJ, Alarcón GS, McGwin G, Roseman JM, Bastian HM, Friedman AW, Baegthe BA, Vilá LM, Reveille JD: Influence of aggressive therapy on development of damage in systemic lupus erythematosus (SLE) using propensity modeling. *Arthritis Rheum* 2003; 48 (suppl): S190.
160. Reveille JD, Bruckel J, Inman R, Mahowald M, Weisman M, Schumacher HR, Khan MA, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JY, Lee J, Jin L: A genome-wide scan in familial ankylosing spondylitis susceptibility. *Arthritis Rheum* 2003; 48 (suppl): S224.
161. Reveille JD, Bruckel J, Inman R, Mahowald M, Weisman M, Schumacher HR, Khan MA, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JY, Lee J, Jin L: Fine mapping of candidate susceptibility regions in ankylosing spondylitis on Chromosome 11q. *Arthritis Rheum* 2003; 48 (suppl): S224
162. Reveille JD, Bruckel J, Inman R, Mahowald M, Weisman M, Schumacher HR, Khan MA, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JY, Lee J, Jin L: Fine mapping of candidate susceptibility regions in ankylosing spondylitis on Chromosome 6q25. *Arthritis Rheum* 2003; 48 (suppl): S224.
163. Reveille JD, Beasley TM, Tan FK, Roeman JM, Vilá LM, Bastian HM, Fessler BJ, Baegthe BA, McGwin G, Allison DB, Alarcón GS: Admixture as a measure of genomic control. Data from a multiethnic lupus cohort. *Arthritis Rheum* 2003; 48 (suppl): S225.
164. Ho KT, Reveille JD, Alarcón GS: The use of hydroxychloroquine in the prevention of thrombosis in systemic lupus erythematosus *Arthritis Rheum* 2003; 48 (suppl): S375.
165. Martin TM, Reveille JD, Rajska BM, Doyle TM, Smith JR, Becker MD, Levinson RD, Wade NK, Schumacher HR, Rosenbaum JT: Evidence for protective HLA alleles in familial acute anterior uveitis. *Arthritis Rheum* 2003; 48 (suppl): S409.
166. Basu D, Williams FM, Reveille JD: Longterm followup of the safety and efficacy of moderate dose corticosteroids in the treatment of diffuse infiltrative lymphocytosis syndrome (DILS). *Arthritis Rheum* 2003; 48 (suppl): S525.
167. Vilá LM, Alarcón GS, Reveille JD: HLA class II alleles among two distinct U.S. Hispanic populations with systemic lupus erythematosus. *Arthritis Rheum* 2003; 48 (suppl): S574.
168. Vilá LM, Alarcón GS, Bastian HM, Fessler BJ, Reveille JD: Lymphopenia early in the course of SLE. Association with clinical manifestations, disease activity and disease damage. *Arthritis Rheum* 2003; 48 (suppl): S575.

169. Bastian HM, Alarcón GS, Fessler BJ, Baethge BA, Vilá LM, Reveille JD: Ethnicity and non-renal disease activity are predictive of worsening proteinuria in systemic lupus erythematosus. *Arthritis Rheum* 2003; 48 (suppl): S578.
170. Bastian HM, Alarcón GS, Vilá LM, Fessler BJ, Baethge BA, Reveille JD: What predicts a rise in creatinine in systemic lupus erythematosus (SLE) patients? *Arthritis Rheum* 2003; 48 (suppl): S579.
171. Tsui FWL, Tsui HW, Stone MA, Payne U, Reveille JD, Patterson AD, Inman RD: A polymorphism in the 5' non-coding region of ANKH is significantly linked to and associated with ankylosing spondylitis in North American families. *Arthritis Rheum* 2003; 48 (suppl): S603.
172. Sanchez ML, Agee B, Bastian HM, Fessler BJ, Baethge BA, Reveille JD, Vilá LM, Alarcón GS: Patient's perception of disease activity, pain and abnormal coping styles are associated with depression in SLE, data from a multiethnic lupus cohort using a 2-item questionnaire. *Arthritis Rheum* 2003; 48 (suppl): S646.
173. Roseman J, McGwin G, Alarcón GS, Baethge BA, Fessler BJ, Bastian HM, Vilá LM, Reveille JD: Predictors of time-to-new-damage in SLE patients from different ethnicities. *Arthritis Rheum* 2003; 48 (suppl): S694.
174. Toloza SM, Uribe AG, Alarcón S, McGwin G, Agee B, Fessler BJ, Bastian HM, Baethge BA, Vilá LM, Roseman JM, Reveille JD: Poverty is a strong predictor of vascular events in SLE patients from different ethnicities. *Arthritis Rheum* 2003; 48 (suppl): S694.
175. Reveille JD, Bruckel J, Inman R, Mahowald M, Weisman M, Schumacher HR, Khan MA, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JY, Lee J, Jin L: A genome-wide scan in familial ankylosing spondylitis susceptibility. *Am J Hum Genet* 2003; 73 (suppl): 500.
176. Lee J, Reveille JD, Luo J, Bruckel J, Weisman M, Khan MA, Inman R, Schumacher HR, Maksymowych WP, Martin TM, Rosenbaum JY, Yu DTY, Stone M, Jin L: Fine mapping of a candidate susceptibility region on chromosome 11 in ankylosing spondylitis. *Am J Hum Genet* 2003; 73 (suppl): 533
177. Luo J, Reveille JD, Lee J, Bruckel J, Weisman M, Khan MA, Inman R, Schumacher HR, Maksymowych WP, Martin TM, Yu DTY, Stone M, Rosenbaum JY, Jin L: Fine mapping of candidate susceptibility regions in ankylosing spondylitis on Chromosome 6q25. *Am J Hum Genet* 2003; 73 (suppl): 533.
178. Martin, T.M., J.D. Reveille, T.M. Doyle, J.R. Smith, B. Rajska, M.D. Becker, R.D. Levinson, N.K. Wade, H.R. Schumacher, J.T. Rosenbaum. Familial Acute Anterior Uveitis: An HLA Analysis. 2003 Annual Meeting Abstract and Program Planner accessed at www.arvo.org. Association for Research in Vision and Ophthalmology. Abstract 2384.
179. Martin TM, Zhang G, Luo J, Jin L, Doyle TM, Coffman JE, et al. A genome wide scan identifies 3 loci predisposing to acute anterior uveitis including on locus unassociated with ankylosing spondylitis [abstract]. In: 2004 Annual Meeting Abstract and Program Planner accessed at www.arvo.org. Association for Research in Vision and Ophthalmology.; 2003
180. Reveille JD, Zhang G, Weisman MH, Bruckel J, H. Schumacher HR, Khan MH, Inman RD, Maksymowych WP, Mahowald M, Martin TM, Yu DTY, Stone M, Rosenbaum JT, Jin L. The Haplotype HLA-B*0700, DRB1*1501, DQA1*0102, DQB1*0602

- Augments the Risk for the Development of AS in Addition to HLA-B27. *Arthritis Rheum* 50 2004; (suppl): S259.
181. Reveille JD, Ward MM, Davis JC, Jin L, Weisman MH. Functional Impairment over Time in Patients with Ankylosing Spondylitis (AS). No Evidence for a Role for HLA-B, DRB1, DQA1, DQB1, DPB1, IL-1RN or MMP3 Genes. *Arthritis Rheum* 2004; 50 (suppl): S213.
 182. Nguyen J, Zhou X, Weisman MH, Ward MM, Davis JC, Reveille JD. A Single Nucleotide Polymorphism of Connective Tissue Growth Factor (CTGF) gene associated with Ankylosing Spondylitis in Caucasian and Hispanic populations. *Arthritis Rheum* 2004; 50 (suppl): S449.
 183. Reveille JD, Zhang G, Weisman MH, Bruckel J, H. Schumacher HR, Khan MH, Inman RD, Maksymowych WP, Mahowald M, Martin TM, Yu DTY, Stone M, Rosenbaum JT, Jin L. Interaction of a Region on Chromosome 11q23 and the HLA-DPB1 Locus Influences Susceptibility to Ankylosing Spondylitis (AS). *Arthritis Rheum* 2004; 50 (suppl): S449.
 184. Michael M. Ward, Michael H. Weisman, John C. Davis, John D. Reveille. Risk Factors for Functional Limitations in Ankylosing Spondylitis: The PSOAS Study. *Arthritis Rheum* 50 2004; (suppl): S618.
 185. Filemon Tan, Bernard Hildebrand, Malisa Lester, Debra Wallis, Dianna Milewicz, Xiadong Zhou, Maureen Mayes, John Reveille, Frank Arnett. Classification Analysis of the Transcriptome of Dermal Fibroblasts from Systemic Sclerosis (SSc) Patients. *Arthritis Rheum* 2004; 50 (suppl): S621.
 186. Jaime Calvo-Alén, Sergio M. Toloza, Mónica Fernández, Holly M. Bastian, Barri J. Fessler, Jeffrey M. Roseman, Gerald McGwin, Jr., Luis M. Vilá, John D. Reveille, Graciela S. Alarcón. Smoking, Hypercholesterolemia and Glucocorticoid (GC) Use Are Major Risk Factors for Venous Thrombosis in Systemic Lupus Erythematosus (SLE). *Arthritis Rheum* 2004; 50 (suppl): S595.
 187. Jaime Calvo-Alén, Gerald McGwin, Jr., Jeffrey M. Roseman, Sergio M. Toloza, Holly M. Bastian, Mónica Fernández, Barri J. Fessler, Luis M. Vilá, John D. Reveille, Graciela S. Alarcón. High-LDL Cholesterol Level is a Risk Factor for, and Hydroxychloroquine (HCQ) Use is Protective of the Development of Osteonecrosis in Systemic Lupus Erythematosus (SLE). *Arthritis Rheum* 2004; 50 (suppl): S595.
 188. Barri J. Fessler, Graciela S. Alarcón, Gerald McGwin, Jr., Luis M. Vilá, Holly M. Bastian, John D. Reveille. Factors Associated with Development of Hypothyroidism in Patients with Systemic Lupus Erythematosus: Data From a Multiethnic Cohort. *Arthritis Rheum* 2004; 50 (suppl): S601.
 189. Mónica Fernández, Jaime Calvo-Alén, Sergio Toloza, Luis Vilá, Barri Fessler, Holly Bastian, Gerald McGwin, Jr., John Reveille, Graciela Alarcón. Menopausal status rather than age is an important determinant of damage accrual in SLE: Data from a large multi-ethnic cohort. *Arthritis Rheum* 2004; 50 (suppl): S690.
 190. Jaime Calvo-Alén, Gerald McGwin, Jr., América Uribe, Jeffrey M. Roseman, Holly M. Bastian, Sergio M. Toloza, Luis M. Vilá, Barri J. Fessler, Mónica Fernández, John D. Reveille, Graciela S. Alarcón. Ethnicity, socioeconomic-demographic, behavioral and psychological variables predict disease activity over time in systemic lupus

- erythematosus (SLE): Data from a large multiethnic cohort. *Arthritis Rheum* 2004; 50 (suppl): S690.
191. Maria Suarez-Almazor, Angela Blanco, John D. Reveille, Maureen Mayes. Disease and symptom burden in systemic sclerosis: the patients' perspective. *Arthritis Rheum* 2004; 50 (suppl): S423.
192. Luis M. Vilá, Graciela S. Alarcón, Jaime Calvo-Alén, Sergio M. Toloza, Gerald McGwin, Jr., Holly M. Bastian, Barri J. Fessler, John D. Reveille. Association of C-Reactive protein with disease activity and damage accrual at initial evaluation in patients with systemic lupus erythematosus. *Arthritis Rheum* 2004; 50 (suppl): S409.
193. Martin TM, Zhang G, Luo J, Doyle TM, Rajska BM, Coffman JE, Smith JR, Becker MD, Mackensen F, Khan MA, Levinson R, Schumacher HR, Wade NK, Li Jin, Reveille JD, Rosenbaum JT. A region on chromosome 9p predisposes to acute anterior uveitis, a specific disease manifestation in ankylosing spondylitis. *Arthritis Rheum* 2004; 50 (suppl): S448.
194. Alexander J. Szalai, Graciela S. Alarcón, Sergio M.A. Toloza, Mark A. McCrory, Jeffrey C. Edberg, Gerald McGwin, Jr., Jaime Calvo-Alén, Holly M. Bastian, Barri J. Fessler, Luis M. Vilá, Robert P. Kimberly, John D. Reveille Association between a Dinucleotide Repeat Polymorphism in the Intron of the C-Reactive Protein (*CRP*) Gene and Vascular Events (VE) in SLE Patients. *Arthritis Rheum* 2004; 50 (suppl): S255.
195. Holly M. Bastian, Jeffrey M. Roseman, Filemon Tan, Barri J. Fessler, Luis M. Vilá, Gerald McGwin, Jr., John D. Reveille, Graciela S. Alarcón. Admixture explains the majority of the effect of ethnicity on the occurrence of lupus nephritis (LN) in patients with systemic lupus erythematosus (SLE). *Arthritis Rheum* 2004; 50 (suppl): S257.
196. Martha L. Sanchez, Graciela S. Alarcón, Barri J. Fessler, Holly M. Bastian, Jeffrey M. Roseman, Qing Lee, Luis M. Vilá, John D. Reveille. Cognitive impairment (CI) in lupus is stable over time and may not be recognized by rheumatologists. Data from a multiethnic cohort. *Arthritis Rheum* 2004; 50 (suppl): S242.
197. Martha L. Sanchez, Holly M. Bastian, Barri J. Fessler, John D. Reveille, Luis M. Vilá, Graciela S. Alarcón. Perception of discrimination in SLE Patients From a multiethnic cohort. *Arthritis Rheum* 2004; 50 (suppl): S241.
198. Graciela S. Alarcón, Jeffrey Edberg, Gerald McGwin, Jr., Michelle Petri, Rosalind Ramsey-Goldman, Luis M. Vilá, Jaime Calvo-Alén, Holly M. Bastian, Barri J. Fessler, John D. Reveille, Robert P. Kimberly. predictors of end-stage renal disease (ESRD) in SLE patients with renal involvement from a multi-ethnic, US multi-institutional, multi-regional cohort. *Arthritis Rheum* 2004; 50 (suppl): S197.
199. Graciela S. Alarcón, John D. Reveille, Gerald McGwin, Jr., Michelle Petri, Rosalind Ramsey-Goldman, Luis M. Vilá, Barri J. Fessler, Jeffrey C. Edberg, Robert P. Kimberly. Predictors of renal involvement in a large multi-ethnic, multi-institutional, multi-regional SLE cohort. *Arthritis Rheum* 2004; 50 (suppl): S197.
200. Reveille JD, Zhang G, Weisman MH, Bruckel J, Inman RD, Khan MA, Schumacher HR, Maksymowych WP, Ward TM, Rosenbaum JT, Yu DT, Davis JC, Ward MM, Jin L. Evidence for involvement of the neural cell adhesion cell (NCAM)-1 gene in susceptibility to ankylosing spondylitis. *Arthritis Rheum* 2005; 52 (suppl): S389.
201. Ward MM, Reveille JD, Davis JC, Weisman M. Specific occupational activities and functional limitations in patients with long-standing ankylosing spondylitis. *Arthritis Rheum* 2005; 52 (suppl): S212.

202. Petri M, Alarcón GS, Kimberly R, Reveille JD. Predictors of renal insufficiency in systemic lupus erythematosus. *Arthritis Rheum* 2005; 52 (suppl): S385.
203. Alarcón GS, McGwin G, Fessler BJ, Bertoli AM, Calvo-Alén J, Bastian HM, Vilá LM, Reveille JD, “Confounding by indication” partially explains the protective effect of hydroxychloroquine (HCQ) in SLE survival: Data from a multiethnic US cohort. *Arthritis Rheum* 2005; 52 (suppl): S726.
204. Nichols DR, Weisman MH, Davis JC, Basu D, Ward MM, Reveille JD. Ankylosing spondylitis in African Americans: A clinical and genetic analysis. *Arthritis Rheum* 2005; 52 (suppl): S394.
205. Mayes MD, Ahn C, Arnett FC, Reveille JD. HLA class II associations in systemic sclerosis (SSc) from the Scleroderma Family Registry and DNA Repository. *Arthritis Rheum* 2005; 52 (suppl): S582.
206. Carter KW, Pluzhnikov A, Timms AE, Miceli-Richard C, Jin L, Wordsworth BP, Cox NJ, Palmer LJ, Breban M, Reveille JD, Brown MA. Meta-analysis of three whole genome linkage scans for ankylosing spondylitis *Arthritis Rheum* 2005; 52 (suppl): S241.
207. Lee W, Davis J, Ward M, Learch T, Reveille J, Weisman M. Is it a boy or a girl? Gender differences in ankylosing spondylitis (AS) that may explain certain clinical features and outcome: results from the PSOAS cohort. *Arthritis Rheum* 2005; 52 (suppl): S639.
208. Reveille JD, Ward MM, Davis JC, Weisman, MH. HLA-B, DRB1, DQA1, DQB1 And DPB1 Alleles do not affect radiographic severity in ankylosing spondylitis. *Arthritis Rheum* 2005; 52 (suppl): S644.
209. Davis JC., Michael M. Ward, Thomas Learch, John D. Reveille, Michael Weisman. Radiographic severity in patients with long-standing ankylosing spondylitis is associated with multiple factors including male gender, age and history of smoking. *Arthritis Rheum* 2005; 52 (suppl): S635.
210. Basu D, Weisman MH, Davis JC, Nichols DR, Ward MM, Reveille JD. HLA-B27 Negative Are Similar To HLA-B27 positive patients with ankylosing spondylitis in radiographic, functional and clinical severity. *Arthritis Rheum* 2005; 52 (suppl): S211.
211. MacNeil MC, Ahn CW, McNearney T, Fischbach M, Feghali-Bostwick C, Fritzler M, Reveille JD, Arnett FC, Mayes MD. Application of the Scleroderma Disease Severity Scale to a multiethnic prospective early disease cohort: Data from the GENISOS (Genes versus Environment in Scleroderma Outcome Study) Cohort. *Arthritis Rheum* 2005; 52 (suppl): S171
212. Cepeda EJ, Williams FM, Ishimori M, Weisman MH, Reveille JD. The use of anti-tumor necrosis factor therapy in HIV positive individuals with rheumatic disease. *Arthritis Rheum* 2005; 52 (suppl): S249.
213. Chaiamnuay S, Bertoli AM, Fernández M, Vilá LM, Reveille JD, Alarcón GS. Increased Body Mass Index (BMI) is Associated with Hypertension (HTN) and Low HDL-Cholesterol in Systemic Lupus Erythematosus (SLE). Data from a Large Multiethnic SLE Cohort. *Arthritis Rheum* 2005; 52 (suppl): S610.
214. Bertoli AM, Fernández M, McGwin G, Tan FK, Fessler BJ, Bastian HM, Vilá LM, Reveille JD, Alarcón GS. Mannose binding lectin (MBL) exon 1 polymorphisms influence SLE manifestations, but not its course or outcome: Data from a large multiethnic cohort. *Arthritis Rheum* 2005; 52 (suppl): S192.

215. Bertoli AM, Fernández M, Vilá LM, Fessler BJ, Bastian HM, Reveille JD, Alarcón GS. Despite lower levels of disease activity, Late-onset lupus patients accrue more damage and experience increased mortality than patients with early-onset lupus: Data from a large multiethnic cohort. *Arthritis Rheum* 2005; 52 (suppl): S184.
216. Bertoli AM, Fernández M, McGwinn G, Vilá LM, Fessler BJ, Bastian HM, Reveille JD, Alarcón GS. Factors predictive of the use of hydroxychloroquine (HCQ) in patients with systemic lupus erythematosus (SLE): Data from a multiethnic cohort. *Arthritis Rheum* 2005; 52 (suppl): S183
217. Fernández M, Bertoli AM, McGwin G, Fessler BJ, Calvo-Alén J, Vilá LM, Bastian HM, Reveille JD, Alarcón GS. Vascular arterial events (VAE) among women with systemic lupus erythematosus (SLE) receiving hormone replacement therapy (HRT) are not increased even after adjusting for confounding by indication. *Arthritis Rheum* 2005; 52 (suppl): S609.
218. Bertoli AM, Fernández M, Apte M, Vilá LM, Fessler BJ, Bastian HM, Reveille JD, Alarcón GS. Lower socio-economic status, disease activity and damage are predictive of self-reported work disability among SLE patients: Data from a large multiethnic cohort. *Arthritis Rheum* 2005; 52 (suppl): S184.
219. Van der Heijde D, Kivitz A, Schiff M, Sieper J, Dijkmans B, Braun J, Dougados M, Reveille J, Wong R, Kupper H, Davis J. Adalimumab therapy results in significant reduction of sign and symptoms in subjects with ankylosing spondylitis: The ATLAS Trial. *Arthritis Rheum* 2005; 52 (suppl): S281.
220. Davis J, Kivitz A, Schiff M, Sieper J, Dijkmans B, Braun J, Dougados M, Reveille J, Wong R, Kupper H, Van der Heijde D. Major clinical response in active ankylosing spondylitis subjects treated with Adalimumab: The ATLAS trial. *Arthritis Rheum* 2005; 52 (suppl): S208.
221. McNearney TA, Fischbach M, Reveille JD, Goel N, Lisse JR, Ahn C, Arnett FC, Mayes MD. Early Pulmonary Involvement In Systemic Sclerosis: Associations with genetic, serologic, sociodemographic and behavioral factors in the GENISOS cohort. *Arthritis Rheum* 2005; 52 (suppl): S172.
222. Garcia-Gonzalez A, Richardson M, Popa-Lisseanu MG, Kallen M, Janssen N, Marcus DM, Reveille JD, Warner N, Cox A, Suarez-Almazor ME. Treatment adherence in ethnically diverse patients with rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Rheum* 2005; 52 (suppl). S659.
223. Zhou X, Xiong M, Ward MM, John C, Davis JC, Zhang G, Luo J, Jin L, Weisman MH, Reveille JD. A genetic network involved in inflammatory reaction may contribute to disease susceptibility to ankylosing spondylitis. *Arthritis Rheum* 2006; 53 (suppl) S364.
224. Uribe A, Fernández M, Apte M, Romero J, Sánchez-Guerrero J, Reveille JD and Alarcón GS. Striking differences in the clinical expression of systemic lupus erythematosus (SLE) patients residing in Mexico and the US. *Arthritis Rheum* 2006; 53 (suppl): S558.
225. L.S. Gensler, Ward MM, Reveille JD, Learch T, Weisman MH, Davis JC. Characteristics of juvenile-onset ankylosing spondylitis versus adult-onset ankylosing spondylitis: Results from the PSOAS Group. *Arthritis Rheum* 2006; 53 (suppl): S491.
226. Tucker LB, Uribe AG, Fernandez M, Vilá LM, Apte M, Reveille JD, Alarcón GS. Clinical differences between juvenile and adult onset patients with SLE: Results from a multiethnic longitudinal study *Arthritis Rheum* 2006; 53 (suppl): S271.

227. Braun J, Cook R, Gladman D, Inman R, Maksymowych W, Landewé R, Mease P, Davis J, van der Heijde D, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, Khan M, O'Shea FD, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale D. The INSPIRE Study Group. INSPIRE lateral flexion: a new method to measure lateral spinal mobility in patients with spondyloarthritis. *Arthritis Rheum* 2006; 53 (suppl): S387.
228. Gladman DD, Inman RD, Cook RR, Maksymowych W, van der Heijde D, Landewe R, Braun J, Davis J, Mease P, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale DJ. The INSPIRE Study Group. International spondyloarthritis inter-observer reliability exercise – the INSPIRE study. *Arthritis Rheum* 2006; 53 (suppl): S494.
229. Ward MM, Reveille JD, Davis JC, Weisman MH. Risk factors for total hip arthroplasty in patients with long-standing ankylosing spondylitis. *Arthritis Rheum* 2006; 53 (suppl): S483.
230. Gladman DD, Inman RD, Cook RR, Maksymowych W, van der Heijde D, Landewe R, Braun J, Davis J, Mease P, Brandt J, Burgos Vargas R, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale DJ. The INSPIRE Study Group. Evaluating enthesitis in patients with spondyloarthritis (SpA): Results from the international spondyloarthritis inter-observer reliability exercise – the INSPIRE study. *Arthritis Rheum* 2006; 53 (suppl): S493.
231. Reveille JD, Zhou X, Ward MM, Davis JC, Learch T, Xiong M, Weisman MH. Interleukin-1 alpha affects susceptibility to but not severity of AS. *Arthritis Rheum* 2006; 53 (suppl): S2059.
232. Bastian HM, Alarcón GS, McGwin G, Vila LM, Fessler BJ, Edberg JC, Kimberly RP, Reveille JD. FCGR2A*GG Alleles are associated with the development of end stage renal disease (ESRD) but not with decreased GFR in patients with biopsy proven lupus nephritis (LN). *Arthritis Rheum* 2006; 53 (suppl): S2099.
233. Vilá LM, Alarcón GS, Bastian HM, Fessler BJ, Reveille JD. Factors associated with pulmonary damage in patients with systemic lupus erythematosus. Data from a multiethnic cohort. *Arthritis Rheum* 2006; 53 (suppl): S594.
234. Vilá LM, Alarcón GS, Bastian HM, Fessler BJ, Apte M, Reveille J. Association of anemia with disease activity and damage accrual in systemic lupus erythematosus. Data from a multiethnic cohort. *Arthritis Rheum* 2006; 53 (suppl): S591.
235. Fernández M, McGwin G, Apte M, Sanchez M, Bastian HM, Fessler BJ, Vilá LM, Reveille JD, Alarcón GS. The Short Form-6D (SF-6D), as a measure of overall health, is a predictor of damage accrual but not of mortality in systemic lupus erythematosus (SLE) patients. *Arthritis Rheum* 2006; 53 (suppl): S584.
236. Alarcón GS, McGwin G, Fernández M, Sanchez ML, Apte M, Fessler B, Bastian H, Vila LM, Reveille JD. Disease activity, pain, fatigue, helplessness, poverty, social support and abnormal coping behaviors contribute to overall poor health in systemic lupus erythematosus (SLE), as determined by the SF-6D index. *Arthritis Rheum* 2006; 53 (suppl): S582.
237. Chaiamnuay S, Bertoli AM, Roseman JM, McGwin G, Apte M, Vilá LM, Reveille JD, Alarcón GS. Predictors of Hypertension (HTN) in Systemic Lupus Erythematosus (SLE). Data from a Multiethnic US Cohort. *Arthritis Rheum* 2006; 53 (suppl): S559.

238. Fernández M, Andrade R, Bastian HM, Fessler BJ, Luis M. Vilá LM, Reveille JD, Alarcón GS. Thrombocytopenia early in the course of systemic lupus erythematosus (SLE) is a predictor of worse disease activity but not of damage accrual or mortality: Data from a multiethnic cohort. *Arthritis Rheum* 2006; 53 (suppl): S583.
239. Albuquerque SM, Ward MM, Diekman L, Zhou X, Davis JC, Weisman MH, Reveille JD. Comparison Of Clinical Features And Genetic Markers In Familial and Sporadic Ankylosing Spondylitis. *Arthritis Rheum* 2006; 53 (suppl): S460.
240. Andrade RM, Alarcón GS, Mónica Fernandez¹, Mandar Apte¹, Luis M. Vilá², Jeffrey C. Edberg¹, Robert P. Kimberly¹, John D. Reveille³, for the LUMINA Study Group. Predictive value of low-binding alleles of FCGR2a for the occurrence of seizures in systemic lupus erythematosus: data from LUMINA, a multiethnic cohort. *Arthritis Rheum* 2006; 53 (suppl); S556.
241. Lopez-Olivo MA, Garcia-Gonzalez A, Kallen MA, Richardson MN, Cox VL, Janssen NM, Marcus DM, Reveille JD, Warner NB, Suarez-Almazor ME. Social Support and Quality of Life in Patients with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). *Arthritis Rheum* 2006; 53 (suppl): S159.
242. Berrios-Rivera JP, Street RL, Garcia-Gonzalez A, Kallen MA, Richardson MN, Janssen NM, Marcus DM, Reveille JD, Warner NB, Cox V, Suarez-Almazor ME. Perceptions of their involvement in care in patients with rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Rheum* 2006; 53 (suppl); S150.
243. Andrade RM, Alarcón GS, Fernandez M, Apte M, Vilá LM, Reveille JD. Accelerated damage accrual among male systemic lupus erythematosus patients: Results from a multiethnic U,S cohort. *Arthritis Rheum* 2006; 53 (suppl); S557.
244. Assassi S, Arnett FC, Reveille JD, Gourh P, Tan FK, Mayes MD. Disease features, disease type, HLA types and autoantibody profile in 17 multicase SSc families. *Arthritis Rheum* 2006; 53 (suppl): S412.
245. Edberg JC, Begovich AB, McGwinn G, Petri M, Ramsey-Goldman R, Vila LM, Reveille JD, Alarcon GS, Kimberly RP. Lack of association of a genetic variant of PTPN22 with African-pAmericans with SLE. *Arthritis Rheum* 2006; 53 (suppl); S184.
246. Garcia-Gonzalez A, Richardson MN, Kendall-Roundtree A, Kallen MA, Cox VL, Janssen N, Marcus DM, Reveille JD, Warner NB, Suarez-Almazor ME. Comparisons between patients' and physicians' perceptions of patients adherence to therapy for rheumatic disease. *Arthritis Rheum* 2006; 53 (suppl): S159.
247. Van der Heijde D, Luo MP, Wordsworth P, Mease PJ, Reveille JD, Zeidler H, Breban M, Westhovens R, Chmiel JJ, Chen N, Wong R, Davis J. Adalimumab improves physical functioning and work productivity in ankylosing spondylitis (AS) patients: Results from ATLAS. *Arthritis Rheum* 2006; 53 (suppl): S103.
248. Garcia-Gonzalez A, Richardson MN, Kallen MA, Cox VL, Janssen N, Marcus DM, Reveille JD, Warner NB, Suarez-Almazor ME. Functional health literacy and numeracy in adults with rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Rheum* 2006; 53 (suppl): S158.
249. Alkassab F, Arnett FC, Reveille JD, Ahn C, McNearney TA, Fischbach M, Estrada-y-Martin R, Feghali-Bostwick C, Fritzler M, Williams L, Mayes MD. Persistence of pulmonary function tests (PFTs) abnormalities in African American systemic sclerosis (SSc) patients compared to Caucasian and Hispanic patients in the GENISOS cohort. ACR/AHRP Program book supplement, 2006; F60.

250. Arango A, Gourh P, Tam FK, Reveille JD, Braun MC. Polymorphism of the C5a receptor in systemic lupus erythematosus. Results from three ethnic groups. ACR/AHRP Program book supplement, 2006; F88.
251. Brown EE, Edberg JC, Petri M, Reveille JD, Vilá LM, Ramsey-Goldman R, Alarcón GA, Kimberly RP. Haplotypes of *IRF5* and SLE-related sequelae. *Arthritis Rheum* 2007; 55 (suppl): S223.
252. Reveille JD, Zhou X, Weisman MH, Ward MM, Davis JC, Martin TM, Rosenbaum JT, Deloukas P, Keniry A, Gwilliam R, McGinnis R, Pointon JJ, Wordsworth BP, Brown MA. IL23R Genes Do Not Distinguish Acute Anterior Uveitis in Patients with Ankylosing Spondylitis. *Arthritis Rheum* 2007; 55 (suppl):S244.
253. Reveille JD, Zhou X, Bradbury LA, Cardon LC, Davis JC, Deloukas P, Evans DM, Keniry A, Gwilliam R, McGinnis R, Pointon JJ, Savage L, Learch TL, Ward MM, Weisman MH, Wordsworth BP, Brown MA. IL23R Genes Are Involved in Susceptibility to But Not Severity of Ankylosing Spondylitis. *Arthritis Rheum* 2007; 55 (suppl): S529.
254. Ward MM, Reveille JD, Davis JC and Weisman MH. Association of radiographic damage with functional limitations in patients with ankylosing spondylitis: Differences between patients with early and long-standing disease. *Arthritis Rheum* 2007; 55 (suppl): S264.
255. Ward MM, Reveille JD, Davis JC and Weisman MH. Impact of ankylosing spondylitis on work and family life: Comparisons to the U.S. population. *Arthritis Rheum* 2007; 55 (suppl): S478.
256. Zhou X, Xiong M, Weisman MH, Inman RD, Khan MA, Schumacher HR, Tammy M, Martin TM, Rosenbaum JT, Maksymowych WP, Diekman L, Reveille JD. Genetic Studies of the interleukin-1A, CTGF, DRB, DQA, DPB, HLA-B and HLA-A in ankylosing spondylitis families. *Arthritis Rheum* 2007; 55 (suppl):S245.
257. Assassi S, Systemic sclerosis and systemic lupus erythematosus have distinct gene expression profiles in the peripheral blood cells. *Arthritis Rheum* 2007; 55 (suppl):S67.
258. González LA, Andrade RM, Fernández M, Apte M, Vilá LM, McGwin G, Jr, Reveille JD, Alarcón GS. Hydroxychloroquine protects lupus patients from developing seizures: Data from a large multiethnic cohort. *Arthritis Rheum* 2007; 55 (suppl): S221.
259. Kelly JA, Edberg JC, Kaufman KM, Kilpatrick J, Bruner GR, Merrill JT, James JA, Marion MC, Langefeld CD, Petri MA, Reveille JD, Ramsey-Goldman R, Vilá LM, Alarcón GS, Kimberly RP, Harley JB. Genetic Association with interferon regulatory factor 5 (*IRF5*) and systemic lupus erythematosus in multiple ethnic groups. *Arthritis Rheum* 2007; 55 (suppl): S229.
260. Lopez-Olivo MA, Kallen MA, Richardson MN, Garcia-Gonzalez A, Cox VL, Lidsky M, Ng B, Marcus D, Reveille JD, Suarez-Almazor M. Treatment adherence and use of reminders in patients with rheumatic disease. *Arthritis Rheum* 2007; 55 (suppl):S110.
261. Lopez-Olivo MA, Kallen MA, Richardson MN, Garcia-Gonzalez A, Cox VL, Lidsky M, Ng B, Marcus D, Reveille JD, Suarez-Almazor M. Effect of depression and social support on the self-reported adherence in patients with rheumatic diseases. *Arthritis Rheum* 2007; 55 (suppl):S118.
262. Gonzalez LA, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS. Systemic lupus erythematosus in a multiethnic us cohort: Predictors of neuropsychiatric damage. *Arthritis Rheum* 2007; 55 (suppl): in press

263. Durán S, McGwin G, Vilá LM, Reveille JD, Alarcón GS. Angiotensin-converting enzyme inhibitor use is associated with a decreased disease activity in patients with systemic lupus erythematosus. Results from a multiethnic US cohort. *Arthritis Rheum* 2007; 55 (suppl): in press
264. Brionez TF, Assassi S, Ward MM, Diekman L, Zhou X, Davis JC, Albuquerque SM, Weisman MH, Reveille JD. Are there clinical or genetic differences between familial and sporadic ankylosing spondylitis? *Arthritis Rheum* 2007; 55 (suppl): in press
265. Ramsey-Goldman R, Alarcón GS, McGwin G, Petri M, Vilá LM, Edberg JC, Reveille JD, Kimberly RP. Time to seizure occurrence and seizure damage in a multi-ethnic lupus cohort. *Arthritis Rheum* 2007; 55 (suppl):S460.
266. Durán S, Apte M, Alarcón GS, Vilá LM, Edberg JC, Kimberly RP, Reveille JD. Association of the *FasL-844*TT/TC* Alleles with hemolytic anemia in patients with systemic lupus erythematosus. Results from a multiethnic US cohort. *Arthritis Rheum* 2007; 55 (suppl):S463.
267. Durán S, McGwin G, Vilá LM, Reveille JD, Alarcón GS¹. Angiotensin-converting enzyme inhibitors may prevent renal involvement in patients with systemic lupus erythematosus. Results from a multiethnic US cohort. *Arthritis Rheum* 2007; 55 (suppl): S463.
268. González LA, Andrade RM, Fernández M, Apte M, Vilá LM, McGwin G, Reveille JD, Alarcón GS. Seizures are important determinants of damage accrual but not of mortality in systemic lupus erythematosus (SLE): Data from a large multiethnic cohort. *Arthritis Rheum* 2007; 55 (suppl): S463.
269. Bertoli AM, Vila LM, Reveille JD, Alarcon G. High Sensitivity C-Reactive Protein (hs-CRP) is associated with early damage in systemic lupus erythematosus (SLE). Data from a multiethnic cohort. *Arthritis Rheum* 2007; 55 (suppl): S464.
270. Sanchez ML, Jhang JS, Vilá LM, Reveille JD, Alarcón GS. Disease activity and alcohol intake may lead to permanent cognitive impairment in patients with systemic lupus erythematosus (SLE): Data from a multiethnic cohort. *Arthritis Rheum* 2007; 55 (suppl):S464.
271. Gladman, DD, Inman RD, Cook RR, van der Heijde D, Landewe R, Braun J, Davis JC., Mease PJ, Brandt J, Burgos-Vargas R, Chandran V, Helliwell P, Kavanaugh AF, O'Shea F, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone M, Taylor W, Veale D, Maksymowych W, The INSPIRE Study Group. Composite indices for disease activity in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). *Arthritis Rheum* 2007; 55 (suppl): S481.
272. González LA, Durán S, McGwin G, Apte M, Vilá LM, Reveille JD, Alarcón GS. Systemic Lupus Erythematosus (SLE) patients of Hispanic-Texan Ethnicity are at increased risk of premature gonadal failure (PGF): Data from a large multiethnic cohort. *Arthritis Rheum* 2007; 55 (suppl): S734.
273. Bertoli AM, Vila LM, Alarcon G, McGwin G, Petri M, Ramsey-Goldman R, Reveille JD, Kimberly RP. factors associated with vascular events in a multiethnic lupus cohort. *Arthritis Rheum* 2007; 55 (suppl): S738.
274. Edberg JC, Wu J, Marion M, Langefeld CD, McGwin G, Petri M, Ramsey-Goldman R, Vilá LM, Reveille JD, Kaufman KM, Frank S, Harley JB, Alarcón G, Kimberly RP. Genetic variation in the CRP promoter: Association with SLE. *Arthritis Rheum* 2007; 55 (suppl): S808.

275. Sanchez ML, Zhang JS, Vilá LM, Reveille JD, Alarcón GS. Factors associated with the development of cognitive impairment over the course of systemic lupus erythematosus (SLE): Data from a multiethnic cohort. *Arthritis Rheum* 2007; 55 (suppl):S826.

PEER-REVIEWED PUBLICATIONS:

1. Costa JL, Murphy DL, Reveille JD: Evaluation of the uptake of various amines into storage vesicles of intact human platelets. *Br J Pharmacol*, 1977; 61:223-230.
2. Reveille JD, Bias WB, Winkelstein JA, Provost TT, Dorsch CA, Arnett FC: Familial systemic lupus erythematosus: Immunogenetic studies in eight families. *Medicine* 1983, 62:21-35.
3. Boling EP, Wen J, Reveille JD, Bias WB, Chused TM, Arnett FC: Primary Sjögren's syndrome and autoimmune hemolytic anemia in sisters: A family study. *Am J Med*, 1983; 74:1066-1071.
4. Reveille JD, Wilson RW, Provost TT, Bias WB, Arnett FC: Primary Sjögren's syndrome and other autoimmune diseases in families: Prevalence and immunogenetic studies in six kindreds. *Ann Int Med*, 1984; 101:748-756.
5. Arnett FC, Reveille JD, Wilson RW, Provost TT, Bias WB: Systemic lupus erythematosus: Current state of the genetic hypothesis. *Semin Arthritis Rheum*, 1984; 14:24-35.
6. Alarcón GS, Sams WM Jr., Barton DD, Reveille JD: Bullous lupus erythematosus rash worsened by dapsone. *Arthritis Rheum* 1984; 27:1071-1072.
7. Reveille JD, Arnett FA, Wilson RW, Bias WB, McLean RH: Null alleles of the fourth component of complement and HLA haplotypes in familial systemic lupus erythematosus. *Immunogenetics*, 1985; 21:299-311.
8. Acton RT, Hodge TW, McDaniel DO, Reveille JD, Napier-Littrell M, Barger BO: HLA restriction fragment length polymorphism association with insulin-dependent diabetes mellitus and the seronegative spondyloarthropathies. *Bioscience Reports* 1985; 5:815-829.
9. Bias WB, Reveille JD, Beaty TH, Meyers DA, Arnett FC: Evidence that autoimmunity in man is a Mendelian dominant trait. *Am J Hum Genet*, 1986; 39:584-602.
10. McDaniel DO, Acton RT, Barger BO, Koopman WJ, Reveille JD: Association of a 9.2 kb Pvu II class I major histocompatibility complex restriction fragment length polymorphism with ankylosing spondylitis. *Arthritis Rheum*, 1987; 30:894-900.
11. Alarcón GS, Reveille JD: Gouty arthritis of the axial skeleton including the sacroiliac joints. *Arch Intern Med*, 1987; 147:2018-2019.
12. Summers MN, Haley WE, Reveille JD, Alarcón GS: Radiographic assessment and psychologic variables as predictors of pain and functional impairment in osteoarthritis of the knee or hip. *Arthritis Rheum*, 1988; 31:204-209.
13. Pruitt RE, Tuminello VV, Reveille JD: Pneumatosis cystoides intestinalis and benign pneumoperitoneum in a patient with antinuclear antibody negative systemic lupus erythematosus. *J Rheumatol* 1988; 15:1575-1577.
14. Arnett FC, Goldstein R, Duvic M, Reveille JD: Major histocompatibility complex genes in systemic lupus erythematosus, Sjögren's syndrome, and polymyositis: *Am J Med*, 1988; 85:(suppl);38-41.
15. Reveille JD, Koopman WJ, Barger BO, Acton RT, McDaniel DO: Restriction fragment

- length polymorphism analysis in ankylosing spondylitis. *Am J Med* 1988; 85:(suppl);48-50.
16. Straaton KV, Chatham WW, Reveille JD, Koopman WJ, Smith S: Clinically significant valvular heart disease in systemic lupus erythematosus. *Am J Med* 1988; 85:645-650.
 17. Hagglund KJ, Haley WE, Reveille JD, Alarcón GS: Predicting individual difference in pain and functional impairment among patients with rheumatoid arthritis. *Arthritis Rheum*, 1989; 32:851-858.
 18. Reveille JD, Goldman RE, Barger BO, Acton RT: Familial polyarteritis nodosa (PAN): A serologic and immunogenetic analysis. *J Rheumatol* 1989; 16:181-185.
 19. Arnett FC, Hamilton RG, Reveille JD, Bias WB, Harley JD, Reichlin M: Genetic studies of Ro (SS-A) and La (SS-B) autoantibodies detected by ELISA in families with systemic lupus erythematosus and primary Sjögren's syndrome. *Arthritis Rheum* 1989; 32:413-419.
 20. Arnett FC, Bias WB, Reveille JD: Genetic studies in Sjögren's syndrome and systemic lupus erythematosus. *J Autoimmunity* 1989; 2: 403-413.
 21. McDaniel DO, Barger BO, Acton RT, Koopman WJ, Reveille JD: AS and a 9.2 kb Pvu II class I HLA DNA restriction fragment. *J Rheumatol*, 1989; 16:141-142.
 22. Olsen ML, Goldstein R, Arnett FC, Duvic M, Pollock M, Reveille JD: C4 a gene deletion and HLA associations in black Americans with systemic lupus erythematosus. *Immunogenetics* 1989; 30:27-33.
 23. Reveille JD, Schrohenloher RE, Acton RT, Barger BO: DNA analysis of HLA-DR and DQ genes in American blacks with systemic lupus erythematosus *Arthritis Rheum* 1989; 32: 1243-1251.
 24. Reveille JD, Bartolucci A, Alarcón GS: Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race and thrombocytopenia, as well as causes of death. *Arthritis Rheum* 1990; 33: 37-48.
 25. Goldstein R, Duvic M, Targoff IN, Reichlin M, McMenemy AM, Reveille JD, Warner NB, Pollack MS, Arnett FC: HLA-D region genes associated with autoantibody responses to histidyl-transfer RNA synthetase (Jo-1) and other translation-related factors in myositis. *Arthritis Rheum* 1990; 33:1240-1248.
 26. Reveille JD, Conant MA, Duvic M: HIV-associated psoriasis, psoriatic arthritis and Reiter's Syndrome. A disease continuum? *Arthritis Rheum* 1990; 33:1574-1578.
 27. Reveille JD, Anderson KL, Schrohenloher RE, Acton RT, Barger BO: RFLP analysis of HLA-DR, DQ, DP and C4 alleles in Caucasians with systemic lupus erythematosus. *J Rheumatol* 1991; 18: 14-18.
 28. Duvic M, Hordinsky MK, Fiedler VC, O'Brien WR, Young R, Reveille JD: HLA-D locus associations in alopecia areata: DRw52a may confer disease resistance. *Arch Derm*, 1991; 127: 64-68.
 29. Arnett FC, Olsen ML, Anderson KL, Reveille JD: Molecular analysis of major histocompatibility complex alleles associated with the lupus anticoagulant. *J Clin Invest* 1991; 87: 1490-1495.
 30. Jacobson DR, Reveille JD, Buxbaum JN: Frequency and genetic background of the position 122 (VAL-ILE) variant transthyretin gene in the black population. *Am J Hum Genet* 1991; 49:192-198.
 31. Reveille JD, MacLeod MJ, Whittington K, Arnett FC: Specific amino acid residues in the second hypervariable region of HLA-DQA1 and DQB1 chain genes promote the Ro (SS-

- A)/La(SS-B) autoantibody responses. *J Immunol* 1991; 146: 3871-3876.
32. Barron KS, Joseph A, MacLeod M, Owerbach D, Reveille JD: DNA analysis of HLA-DR, DQ and DP genes in particular juvenile rheumatoid arthritis. *J Rheumatol* 1991; 18: 1723-1729.
 33. Reveille JD, Barger BO, Hodge TW: HLA-DR2-DRB1 allele frequencies in DR2-positive American blacks with and without systemic lupus erythematosus. *Tissue Antigens*, 1991; 38:178-180.
 34. Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC: Racial differences in the frequencies of scleroderma-related autoantibodies. *Arthritis Rheum* 1992; 35:216-218.
 35. Reveille JD, Owerbach D, Goldstein R, Moreda R, Isern RA, Arnett FC: Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere antibody response in systemic sclerosis (scleroderma). *J Clin Invest* 1992; 89: 1208-1213.
 36. Reveille JD, Brady J, MacLeod-St.Clair M, Durban E: HLA-DPB1 alleles and autoantibody subsets in systemic lupus erythematosus, Sjögren's syndrome and progressive systemic sclerosis: A question of disease relevance. *Tissue Antigens* 1992; 40: 45-48.
 37. Barron KS, Silverman ED, Gonzales JC, St.Clair M, Anderson K, Reveille JD: MHC class II alleles in Kawasaki syndrome - lack of consistent correlation with disease or cardiac involvement. *J Rheumatol* 1992; 19: 1790-1793.
 38. Barron KS, Silverman ED, Gonzales JC, Owerbach D, Reveille JD: DNA analysis of HLA-DR, DQ, and DP alleles in children with polyarticular juvenile rheumatoid arthritis. *J Rheumatol* 1992; 19: 1611-1616.
 39. Tomana M, Schrohenloher RE, Reveille JD, Arnett FC, Koopman WJ: Abnormal galactosylation of serum IgG in patients with systemic lupus erythematosus and members of families with high frequency of autoimmune diseases. *Rheumatol Int* 1992; 12:191-194.
 40. Reveille JD, Durban E, MacLeod MJ, Goldstein R, Moreda R, Altman RD, Arnett FC: Association of amino acid sequences in the HLA-DQB1 first domain with the anti-topoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). *J Clin Invest* 1992; 90:973-980.
 41. Barron KS, Silverman ED, Gonzales J, Arnett FC, Reveille JD: Childhood-onset systemic lupus erythematosus (SLE): A clinical, serologic and immunogenetic analysis. *Arthritis Rheum* 1993; 36: 348-354.
 42. Reveille JD, Arnett FC: Frequencies of scleroderma-related autoantibodies in patients meeting American College of Rheumatology Criteria for systemic sclerosis. *Arthritis Rheum* 1993; 36: 1333-1334.
 43. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcón GS: aCL in systemic lupus erythematosus: Clinical correlates, HLA associations, and impact on survival. *J Rheumatol* 1993; 20:1684-1693.
 44. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcón GS: Survival impact of autoantibodies in systemic lupus erythematosus. *J Rheumatol* 1994; 21: 224-228.
 45. Duvic M, Crane MM, Conant M, Mahoney SE, Reveille JD, Lehrman SN: Zidovudine improves psoriasis in human immunodeficiency virus-positive males. *Arch Dermatol* 1994; 130:447-451.
 46. Reveille JD, Suarez-Almazor ME, Russell AS, Go RCP, Appleyard J, Barger BO, Acton

- RT, Koopman WJ, McDaniel DO: HLA in ankylosing spondylitis. Is HLA-B27 the only MHC gene involved in disease pathogenesis. *Semin Arthritis Rheum* 1994; 23:295-309.
47. Karam NE, Roger L, Reveille JD: Rheumatoid nodulosis of the meninges. *J Rheumatol*, 1994; 21:1960-1963.
 48. Welsh EA, Clark HH, Epstein SZ, Reveille JD, Duvic M: HLA-DQB1*03 alleles are associated with alopecia areata. *J Invest Dermatol* 1994; 103:758-763.
 49. Buyon JP, Slade SG, Reveille JD, Hamel JC, Chan EK: Autoantibody responses to the “native 52-kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus, and Sjogren’s syndrome. *J Immunol* 1994; 152: 3675-3684.
 50. Lee JE, Reveille JD, Ross MI, Platsoucas CD: HLA-DQB1*0301 association with increased cutaneous melanoma risk. *Int J Cancer* 1994; 59: 510-513.
 51. Olsen, ML, Arnett, FC, Reveille, JD: Contrasting molecular patterns of MHC class II alleles associated with the anti-Sm and anti-RNP precipitation autoantibodies in systemic lupus erythematosus. *Arthritis Rheum* 1994; 36: 94-104.
 52. Barron KS, Reveille JD, Carrington M, Mann DL, Robinson MA: Susceptibility to Reiter's syndrome is associated with alleles of TAP genes. *Arthritis Rheum* 1995; 38:684-689.
 53. Reveille JD, Moulds JM, Arnett FC: Major Histocompatibility Complex Class II and C4 Alleles in Mexican Americans with Systemic Lupus Erythematosus. *Tissue Antigens* 1995; 45: 91-97.
 54. Marintchev LM, Naumova EJ, Rashkov RK, Arnett FC, Reveille JD: HLA-Class II Alleles and Autoantibodies in Bulgarians with Systemic Lupus Erythematosus. *Tissue Antigens* 1995; 46: 422-425.
 55. Krylov M, Erdesz S, Alexeeva L, Benevolenskaya L, Arnett FC, Reveille JD: HLA-Class II and HLA-B27 Oligotyping in Two Siberian Native Population Groups. *Tissue Antigens* 1995, 46: 382-386.
 56. Sharma A, Baethge BA, Lisse JR, Vaidya S, Reveille JD. Human leucocyte antigen typing in rheumatoid arthritis/polymyositis overlap syndrome. *Ann Rheum Dis* 1995; 54: 780-781.
 57. Krylov MY, Reveille JD, Alexeeva LI, Erdesz S, Arnett FC, Benevolenskaya LI: HLA-B27 Subtypes Among the Chukotka Native Groups. *Archivum Immunol Therapiae Experimentalis* 1995; 43: 135-138.
 58. McDaniel DO, Alarcón GS, Pratt PW, Reveille JD: Most African-American Patients with Rheumatoid Arthritis do not have the Rheumatoid Antigenic Determinant (Epitope). *Ann Intern Med* 1995; 123: 181-187.
 59. Duvic M, Welsh EA, Jackow C, Papadopoulos E, Reveille JD, Amos C: Analysis of HLA-D Locus Alleles in Alopecia Areata Patients and Families. *J Invest Dermatol* 1995; 104: 5S-6S.
 60. Reveille JD, Arnett FC, Olsen ML, Sakkas LP, Papasteriades C, Moutsopoulos HM: HLA-class II Alleles and C4 Null Genes in Greeks with Systemic Lupus Erythematosus. *Tissue Antigens* 1995; 46: 417-421.
 61. Perl A, Colombo E, Dai H, Agarwal R, Banki K, Poiesz BJ, Phillips PE, Hoch SO, Reveille JD, Arnett FC: Autoantibody Reactivity to the Endogenous Retroviral Element HRES-1-Encoded Antigen Constitutes a Distinct Entity in Patients with Systemic Lupus Erythematosus and Overlap Syndromes. A Comprehensive Study of Antinuclear Antibodies and HLA-Class II Alleles. *Arthritis Rheum* 1995; 38: 1660-1671.

62. Milewicz DM, Byers PH, Reveille JD, Hughes AL, Duvic M: A dimorphic Alu Sb-like insertion in the ethnic-specific. *J Mol Evol* 1996; 42: 117-123.
63. Hirsch R, Miller SM, Kazi S, Cate TR, Reveille JD: HIV-Associated Atypical Mycobacterial Skeletal Infections: A Report of Six Cases and Review of the Literature. *Semin Arthritis Rheum* 1996; 25: 347-356.
64. Lee JE, Loflin PT, Laud PR, Lu M, Reveille JD, Lawlor DA: The Human Leukocyte Antigen TAP2 Gene Defines the Centromeric Limit of Melanoma Susceptibility on Chromosome 6p. *Tissue Antigens* 1996; 47: 117-121.
65. Arnett FC, Reveille JD, Goldstein R, Pollard KM, LeRoy EC, Fritzler MJ: Autoantibodies to Fibrillarin in Systemic Sclerosis (Scleroderma): An Immunogenetic, Serological and Clinical Analysis. *Arthritis Rheum* 1996; 39: 1151-1160.
66. Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, Cameron HD, Paxton G, Hodge T, Weathers E, and Reveille JD: Increased Prevalence of Systemic Sclerosis (Scleroderma) in a Native American Tribe in Oklahoma: Association with an Amerindian HLA haplotype. *Arthritis Rheum* 1996; 39: 1362-1370.
67. Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD: Interrelationships of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. *Arthritis Rheum* 1996; 39: 1507-1518.
68. Kazi S, Cohen PR, Reveille JD: The Diffuse Infiltrative Lymphocytosis Syndrome: Clinical and Immunogenetic Features in 35 Patients. *AIDS* 1996; 10: 385-391.
69. Lee JE, Lu M, Bell B, Mansfield PF, Reveille JD, Ross MI: Malignant Melanoma: Relationship of the Human Leukocyte Antigen Class II Gene DQB1*0301 to Disease Recurrence in AJCC Stage I or II Melanoma Patients. *Cancer* 1996; 758-763.
70. Lee JE, Reveille JD, Platsoucas CD. Association of HLA-DQB1*0301 with malignant melanoma. *J Immunother Emphasis Tumor Immunol.* 1996; 19: 381-385.
71. Reveille JD, Alarcón GS, Fowler SE, Pillemer SR, Neuner R, Clegg DO, Mikhail IS, Trentham DE, Leisen JCC, Bluhm G, Cooper SM, Duncan H, Tuttleman M, Heyse SP, Sharp JT, Tilley B: HLA-DRB1 Genes and Disease Severity in Rheumatoid Arthritis. *Arthritis Rheum* 1996; 39: 1802-1807.
72. Lee JE, Lowy AW, Thompson WA, Lu M, Loflin PT, Skibber JM, Evans DB, Curley SA, Mansfield PF, Reveille JD: Association of Gastric Adenocarcinoma with the HLA Class II Gene DQB1*0301. *Gastroenterology* 1996; 111: 426-432.
73. Arnett FC, Reveille JD, Moutsopoulos HM, Elkon KB: Ribosomal P autoantibodies in systemic lupus erythematosus: Frequencies in Different Ethnic Groups and clinical and Immunogenetic Associations. *Arthritis Rheum* 1996; 39:1833-1839.
74. Rattner JB, Rees J, Arnett FC, Reveille JD, Goldstein R, and Fritzler MJ: The centromere kinesin-like protein, CENP-E: An autoantigen in systemic sclerosis. *Arthritis Rheum* 1996; 39: 1355-1361.
75. Lu M, Thompson WA, Lawlor DA, Reveille JD, Lee JE: Rapid Direct Determination of HLA-DQB1*0301 in The Whole Blood of Normal Individuals and Cancer Patients by Specific Polymerase Chain Reaction Amplification. *J Immunol Meth* 1996; 199: 61-68.
76. Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M: HLA-DR5 and DQB1*03 Class II Alleles are Associated with Cutaneous T-cell lymphoma. *J Invest. Dermatol* 1996; 107: 1-4.
77. Moulds JM, Reveille JD, Arnett FC.: Structural polymorphisms of complement receptor

- 1 (CR1) in systemic lupus erythematosus (SLE) patients and normal controls of three ethnic groups. *Clin Exp Immunol* 1996; 105:302-305.
78. Arnett FC, Reveille JD, Valdez BC: Autoantibodies to a nucleolar RNA helicase protein in patients with connective tissue diseases. *Arthritis Rheum* 1997; 40:1487-1492.
79. Georgescu L, Arnett FC, Reveille JD, Elkon KB: Anti-P antibodies and neuropsychiatric lupus erythematosus. *Proc NY Acad Sci* 1997; 823:263-269.
80. Reveille JD, Moulds JM, Ahn C, Friedman A, Baetghe B, Roseman MD, Straaton K, Alarcón G: Systemic lupus erythematosus in three ethnic groups I: The effects of HLA-class II, C4 and CR1 alleles, Socioeconomic factors and ethnicity at disease onset. *Arthritis Rheum* 1998; 41: 1161-1172.
81. Williams FM, Cohen PR, Jumshyd J, Reveille JD: The prevalence of the diffuse infiltrative lymphocytosis syndrome (DILS) among HIV-1 positive outpatients. *Arthritis Rheum* 1998; 41: 863-868.
82. Alarcón GS, Roseman J., Bartolucci AA, Friedman AW, Moulds JM, Goel N, Straaton KV, Reveille JD: Systemic lupus erythematosus in three ethnic groups, II: features predictive of disease activity early in its course. *Arthritis Rheum* 1998; 41: 1173-1180.
83. Day HM, Thiagarajan P, Ahn C, Reveille JD, Tinker KF, Arnett FC. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. *J Rheumatol.* 1998; 25: 667-674.
84. Zonana-Nacach A, Alarcón GS, Reveille JD, Triana-Alexander M, Alexander RW, Bradley LA: Clinical features of ANA-positive and ANA-negative patients with Fibromyalgia. *J Clin Rheumatol* 1998; 4: 52-56.
85. Alarcón GS, Friedman A, Straaton KV, Moulds JM, Lisse J, Bastian HM, McGwin Jr. G, Bartolucci AA, Roseman JM, Reveille JD. Systemic lupus erythematosus in three ethnic groups: III A comparison of characteristics early in the natural history of the LUMINA cohort. *Lupus* 1999; 8: 197-209.
86. Tan FK, Stivers DN, Arnett FC, Chakraborty R, Howard R, Reveille JD. HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). *Tissue Antigens* 1999; 53: 74-80.
87. Friedman AW, Alarcón GS, McGwin G, Straaton, Roseman J, Goel N, Reveille JD: Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. *Arthritis Care Res* 1999; 12: 256-266.
88. Alarcón GS, Rodriguez JL, Benavides G, Brooks K, Kurusz H, Reveille JD: Systemic lupus erythematosus in three ethnic groups V. Acculturation, health-related attitudes and behaviors and disease activity in Hispanic patients from the LUMINA cohort. *Arthritis Care Res* 1999; 12: 267-276.
89. Arnett FC, Thiagarajan P, Ahn C, Reveille JD: Associations of anti-beta2-glycoprotein autoantibodies with HLA class II alleles in three ethnic groups. *Arthritis Rheum* 1999; 42: 268-274.
90. de Andrade M, Jackow CM, Dahm N, Hordinsky M, Reveille JD, Duvic M: Alopecia areata in families: Association with the HLA locus. *J Investig Dermatol Symp Proc* 1999; 4:220-223.
91. Ioannidis JP, Tektonidou MG, Vlachoyiannopoulos PG, Stavropoulos-Giokas C,

- Spyropoulou-Vlachou M, Reveille JD, Arnett FC, Moutsopoulos HM: HLA associations of anti-beta2 glycoprotein I response in a Greek cohort with antiphospholipid syndrome and meta-analysis of four ethnic groups. *Hum Immunol* 1999; 60: 1274-1280.
92. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger H: Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. *Arch Pathol Lab Med* 2000; 124:71-81.
 93. Zonana-Nacach A, Roseman JM, McGwin G Jr, Friedman AW, Baethge BA, Reveille JD, Alarcón GS: Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. *LUpus in MInority populations: NAture vs Nurture*. *Lupus* 2000; 9: 101-109.
 94. Tan FK, Reveille JD, Arnett FC, Stivers DN, Tsao BP: Poly(ADP)-ribose polymerase and susceptibility to systemic lupus erythematosus and primary antiphospholipid syndrome: comment on the article by Delrieu et al. *Arthritis Rheum* 2000; 43: 1421-1423.
 95. Tan FK, Arnett FC, Reveille JD, Ahn C, Antohi S, Sasaki T, Nishioka K, Bona CA: Autoantibodies to fibrillin 1 in systemic sclerosis: Ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. *Arthritis Rheum* 2000; 43: 2464-2471.
 96. Diekman LA, Wells TD, Reveille JD, Moulds JM. Frequency of HLA-DQB*06 in Caucasian, African American, and Mexican American patients with a positive direct antiglobulin test. *Immunohematol.* 2000; 16: 74-77.
 97. Reveille JD: The changing spectrum of rheumatic disease in human immunodeficiency virus infection. *Semin Arthritis Rheum* 2000; 30: 147-166.
 98. Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J, Fritzler MJ, Ahn C, Arnett FC: Systemic sclerosis in three U.S. ethnic groups: a comparison of clinical, sociodemographic, serologic and immunogenetic determinants. *Semin Arthritis Rheum* 2001; 30: 332-346.
 99. Zuñiga R, Ng S, Reveille JD, Baethge BA, Alarcón GS, Salmon JE. Independent contribution to the risk of nephritis by allelic variants of FcγRIIa and FcγRIIIa in Hispanic patients with systemic lupus erythematosus. *Arthritis Rheum* 2001; 44:361-367 .
 100. Tew MB, Ahn CW, Friedman AW, Reveille JD, Tan FK, Alarcón GS, Bastian HM, Fessler BJ, McGwin G, Lisse JR: Systemic lupus erythematosus from three ethnic groups: Glutathione S-Transferase null alleles lack association with disease manifestations. *Arthritis Rheum* 2001; 44: 981-983.
 101. Johnson RW, Reveille JD, McNearney T, Fischbach M, Friedman, AW, Ahn C, Arnett FC, Tan: Lack Of Association Of A Functionally Relevant Single Nucleotide Polymorphism Of Matrix Metalloproteinase-1 Promoter With Systemic Sclerosis (Scleroderma). *Genes & Immunity*, 2001; 2: 273-275.
 102. Ahmed SS, Arnett FC, Smith CA, Ahn C, Reveille JD: HLA-DRB1 alleles predict the development of methotrexate-induced accelerated rheumatoid nodulosis syndromes in patients with rheumatoid arthritis. *Medicine*, 2001; 80: 271-278.
 103. Tew MB, Reveille JD, Arnett FC, Friedman AW, McNearney T, Fischbach M, Ahn C, Tan FK: Glutathione S-transferase genotypes in systemic sclerosis and their association with clinical manifestations in early disease. *Genes & Immunity* 2001; 2: 236-238.
 104. Alarcón GS, McGwin G, Bastian HM, Roseman J, Lisse J, Fessler BJ, Friedman

- AW, Reveille JD: Systemic Lupus Erythematosus in three ethnic groups: VII. Predictors of mortality in the LUMINA cohort. *Arthritis Rheum* 2001; 45: 191-202.
105. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes M: Familial recurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. *Arthritis Rheum* 2001; 44: 1359-1362.
 106. Tew MB, Johnson RW, Reveille JD, Tan FK: A molecular analysis of low serum deoxyribonuclease activity in lupus patients. *Arthritis Rheum* 2001; 44: 2446-2447.
 107. Zhou X, Tan FK, Xiong M, Milewicz DM, Feghali CA, Fritzler MJ, Reveille JD, Arnett FC: Systemic Sclerosis (Scleroderma): Specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. *J Immunol* 2001; 167: 7126-7133.
 108. Alarcón GS, McGwin G, Jr., Bartolucci A, Roseman JM, Baethge B, Fessler B, Bastian HM, Friedman AW, Reveille JD for the LUMINA Study Group: Systemic lupus erythematosus in three ethnic groups, the LUMINA Study: IX. Differences in damage accrual. *Arthritis Rheum* 2001; 44:2797-2806.
 109. Bastian HM, Roseman JM, McGwin G, Jr., Alarcón GS, Friedman AW, Fessler BJ, Baethge G, Reveille JD, for the LUMINA Study Group: Systemic lupus erythematosus: X. Risk factors for lupus nephritis after diagnosis. *Lupus* 2002; 11: 152-60.
 110. Alarcón G.S., McGwin G, Petri M, Ramsey-Goldman R, Reveille JD, Kimberly R: Baseline characteristics of a multiethnic lupus cohort: PROFILE. *Lupus* 2002; 11: 95-101.
 111. Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI: Presence of the HLA Class II gene *DRB1*1101* predicts interferon- γ levels and disease recurrence in melanoma patients. *Ann Surg Oncol* 2002; 9:587-93.
 112. Alarcón GS, McGwin G Jr, Bastian HM, Fessler BJ, Baethge BA, Friedman AW, Reveille JD; SLE in three ethnic groups XIII. the 'weighted' criteria as predictors of damage. *Lupus*. 2002; 11:329-31.
 113. Rupert KL, Moulds JM, Yang Y, Arnett FC, Warren RW, Reveille JD, Myones BL, Blanchong CA, Yu CY. The Molecular Basis of Complete Complement C4A and C4B Deficiencies in a Systemic Lupus Erythematosus Patient with Homozygous C4A and C4B Mutant Genes. *J Immunol*. 2002; 169: 1570-1578.
 114. Alarcón GS, Cianfrini L, Bradley L, Sanchez ML, Brook K, Friedman AW, Baethge BA, Fessler BJ, Bastian HM, Roseman J, McGwin G, Jr., Reveille JD, for the LUMINA study group: Systemic lupus erythematosus in three ethnic groups: XII. Measuring Cognitive Impairment with the cognitive symptoms inventory. *Arthritis Rheum* 2002; 47:310-9.
 115. Alarcón GS, McGwin G, Jr., Brooks K, Roseman JM, Bastian HM, Fessler BJ, Sanchez ML, Friedman AW, Baethge BA, Reveille JD. Systemic lupus erythematosus in three ethnic groups: XI. Sources of discrepancy in perception of disease activity: A comparison of physician and patient visual analog scale scores. *Arthritis Rheum* 2002; 47:408-13.
 116. Tew MB, Arnett FC, Reveille JD, Tan FK. Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. *Arthritis Rheum*. 2002; 46: 2829-30
 117. Zhou X, Tan FK, Reveille JD, Wallis D, Milewicz DM, Ahn C, Wang A, Arnett FC. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts

- and with susceptibility to scleroderma. *Arthritis Rheum.* 2002; 46: 2990-9.
118. Tsui FW, Tsui HW, Cheng EY, Stone M, Payne U, Reveille JD, Shulman MJ, Paterson AD, Inman RD. Novel genetic markers in the 5'-flanking region of ANKH are associated with ankylosing spondylitis. *Arthritis Rheum.* 2003; 48:791-7.
 119. Johnson RW, Williams FM, Kazi S, Dimachkie M, Reveille JD: HIV-associated polymyositis: A longitudinal study of outcome. *Arthritis Rheum* 2003; 49: 172-8.
 120. Reveille JD, Solomon DH and the ACR Ad Hoc Committee on Immunological Testing Guidelines. Evidence-based guidelines for the use of immunological laboratory tests: Anti-centromere, Scl-70 and nucleolar antibodies. *Arthritis Rheum* 2003; 49: 399-412.
 121. Friedman AW, Tew MB, Ahn C, McGwin G Jr, Fessler BJ, Bastian HM, Baethge BA, Reveille JD, Alarcón GS. Systemic lupus erythematosus in three ethnic groups: XV. Prevalence and correlates of fibromyalgia. *Lupus.* 2003; 12: 274-9.
 122. Calvo-Alen J, Reveille JD, Rodriguez-Valverde V, McGwin G Jr, Baethge BA, Friedman AW, Alarcón GS. Clinical, immunogenetic and outcome features of Hispanic systemic lupus erythematosus patients of different ethnic ancestry. *Lupus* 2003; 12: 377-85.
 123. Maksymowych WP, Reeve J, Reveille JD, Akey JM, Buenviaje H, O'Brien L, Peloso P, Thomson G, Jin L, Russell AS. High throughput single nucleotide polymorphism (SNP) analysis of the Interleukin-1 receptor antagonist (IL-1 RN) Locus in patients with ankylosing spondylitis (AS) by MALDI-TOF mass spectroscopy. *Arthritis Rheum,* 2003; 48: 2011-8.
 124. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, and Furst DE: Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. *J Rheumatol.* 2003; 30: 1630-47.
 125. Alarcón GS, Roseman JM, McGwin G Jr, Uribe A, Bastian HM, Fessler BJ, Baethge BA, Friedman AW, Reveille JD. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. *Rheumatology (Oxford).* 2003; 42: 1-4.
 126. Zhou X, Tan FK, Wang N, Xiong M, Maghidman S, Reveille JD, Milewicz DM, Chakraborty R, Arnett FC: Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. *Arthritis Rheum.* 2003; 48: 2585-92.
 127. Vila LM, Alarcón GS, McGwin G Jr, Friedman AW, Baethge BA, Bastian HM, Fessler BJ, Reveille JD. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. *Rheumatology (Oxford).* 2004; 43: 358-363.
 128. Alarcón GS, McGwin G Jr, Sanchez ML, Bastian HM, Fessler BJ, Friedman AW, Baethge BA, Roseman J, Reveille JD. Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity. *Arthritis Rheum.* 2004; 51: 73-77.
 129. Uribe AG, Alarcón GS, Sanchez ML, McGwin G Jr, Sandoval R, Fessler BJ, Bastian HM, Friedman AW, Baethge BA, Reveille JD. Systemic lupus erythematosus in three ethnic groups. XVIII. Factors predictive of poor compliance with study visits. *Arthritis Rheum.* 2004; 51: 258-63.
 130. Alarcón GS, McGwin G Jr, Uribe A, Friedman AW, Roseman JM, Fessler BJ,

- Bastian HM, Baethge BA, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. *Arthritis Rheum.* 2004;51: 465-74.
131. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. *Arthritis Rheum.* 2004; 51: 800-4.
132. Zhang G, Luo J, Bruckel J, Weisman M, Schumacher HR, Khan MA, Inman R, Mahowald M, Maksymowych W, Martin TM, Yu DTY, Stone M, Rosenbaum JT, Newman P, Lee J, McClain JA, West OC, Jin L, Reveille JD: Genetic studies in familial ankylosing spondylitis susceptibility. *Arthritis Rheum* 2004; 50: 2246-54.
133. Alarcon GS, McGwin G Jr, Roseman JM, Uribe A, Fessler BJ, Bastian HM, Friedman AW, Baethge B, Vila LM, Reveille JD. Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis. *Arthritis Rheum.* 2004; 51: 609-15.
134. Arnett FC, Reveille JD, O'Hanlon TP. HLA-DRB1 alleles in a Caucasian population from Houston, Texas. *Human Immunol* 2004; 65: 1238-1241.
135. Uribe AG, Vilá LM, McGwin G, Sanchez ML, Reveille JD, Alarcón GS. The SLAM-R, the MEX-SLEDAI and a modified SLEDAI-2k are adequate instruments to measure disease activity in systemic lupus erythematosus. *J Rheumatol* 2004; 31: 1934-40.
136. Jin L, Weisman MA, Zhang G, Ward MM, Akey JM, Bruckel J, Inman RD, Luo J, Khan MA, Schumacher HR, Maksymowych WP, Mahowald ML, Sawitzke AD, Vasey FB, Yu DTY, Stone MA, Wang Y, Lee J, Reveille JD. Lack of Association and Linkage of IL1RN Genotypes with Ankylosing Spondylitis Susceptibility. *Arthritis Rheum* 2004; 50: 3047-8.
137. Toloza SMA, Roseman JM, Alarcón GS, McGwin G, Uribe AG, Fessler BJ, Bastian HM, Vilá LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXII. Predictors of time to the occurrence of damage for the first time. *Arthritis Rheum* 2004; 50: 3177-3186.
138. Uribe AG, Ho KT, Agee B, McGwin G Jr, Fessler BJ, Bastian HM, Reveille JD, Alarcon GS. Relationship between adherence to study and clinic visits in systemic lupus erythematosus patients: data from the LUMINA cohort. *Lupus.* 2004; 13: 561-8.
139. Khorshid O, Hosing C, Bibawi S, Ueno N, Reveille J, Mayes MD, Champlin RE. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. *J Rheumatol.* 2004; 31: 2513-6.
140. Toloza SMA, Uribe AG, Alarcón GS, McGwin G, Agee BS, Fessler BJ, Bastian HM, Vilá LM, Shoenfeld Y, Wu R, Roseman JM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XXIII: Baseline predictors of vascular events. *Arthritis Rheum.* 2004; 50:3947-57.
141. Jin L, Weisman M, Zhang G, Ward M, Luo J, Bruckel J, Inman R, Khan MA, Schumacher HR, Maksymowych WP, Mahowald M, Martin T, Rosenbaum JT, Yu DTY, Stone M, Watson J, Dickman E, Davis J, Reveille JD. Lack of association of matrix metalloproteinase 3 (MMP3) genotypes with ankylosing spondylitis susceptibility and severity. *Rheumatology* 2005; 44: 55-60.
142. Martin TM, Zhang G, Luo J, Jin L, Doyle TM, Rajska BM, Coffman JE, Smith JR, Becker MD, Mackensen F, Khan MA, Levinson R, Schumacher HR, Wade NK,

- Rosenbaum JT, Reveille JD. A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease. *Arthritis Rheum* 2005; 52: 269-274.
143. Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FWL. *ANKH* variants associated with ankylosing spondylitis: Gender differences. *Arthritis Res Ther*, 2005; 7: 513-25.
 144. Tan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, Wallis DD, Milewicz DM, Reveille JD, Mayes MD, Jin L, Arnett FC Jr. Classification analysis of the transcriptome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. *Arthritis Rheum*. 2005;52: 865-876
 145. Szalai AJ, Alarcon GS, Calvo-Alen J, Toloza SM, McCrory MA, Edberg JC, McGwin G Jr, Bastian HM, Fessler BJ, Vila LM, Kimberly RP, Reveille JD. Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. *Rheumatology (Oxford)*. 2005; 44: 864-868;
 146. Calvo-Alen J, Vila LM, Reveille JD, Alarcon GS. Effect of ethnicity on disease activity in systemic lupus erythematosus. *J Rheumatol*. 2005 May;32(5):962-963.
 147. Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, Baethge BA, Vila L, Reveille JD. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. *Arthritis Rheum*. 2005; 52: 1473-1480
 148. Fernandez M, Calvo-Alen J, Alarcon GS, Roseman JM, Bastian HM, Fessler BJ, McGwin G Jr, Vila LM, Sanchez ML, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. *Arthritis Rheum*. 2005; 52: 1655-1664.
 149. Monos DS, Pappas J, Magira EF, Gaughan J, Aplenc R, Sakkas L, Freedman R, Reveille JD, Platsoucas CD. Identification of HLA-DQ α 1 and DR β 1 residues associated with susceptibility to epithelial ovarian cancer. *Hum Immunol* 2005; 66: 554-562.
 150. Calvo-Alen J, Alarcon GS, Campbell Jr R, Fernandez M, Reveille JD, Cooper GS. Lack of recording of systemic lupus erythematosus in the death certificates of lupus patients. *Rheumatology (Oxford)*. 2005; 44: 1186-1189
 151. Ho KT, Ahn CW, Alarcon GS, Baethge BA, Tan FK, Roseman J, Bastian HM, Fessler BJ, McGwin Jr G, Vila LM, Calvo-Alen J, Reveille JD. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. *Rheumatology (Oxford)*. 2005; 44: 1303-1307
 152. Sarkar K, Weinberg CR, Oddis CV, Medsger TA, Plotz PH, Reveille JD, Arnett FC, Targoff IN, Genth E, Love LA, Miller FW. Seasonal influence in the onset of serologic groups of idiopathic inflammatory myopathies. *Arthritis Rheum*, 2005; 52: 2433-2438.
 153. O'Hanlon TP, Mercatante-Carrick D, Arnett FC, Reveille JD, Carrington M, Oddis CV, Morel P, Malley JD, Malley K, Dreyfuss J, Shamim E, Rider LG, Chanock SJ, Foster C, Bunch T, P, Miller FW. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. *Medicine (Baltimore)*. 2005 Nov;84(6):338-49.
 154. Calvo-Alen J, Toloza SM, Fernandez M, Bastian HM, Fessler BJ, Roseman JM, McGwin G Jr, Vila LM, Reveille JD, Alarcon GS. Systemic lupus erythematosus in a

- multiethnic US cohort (LUMINA): XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. *Arthritis Rheum.* 2005; 52:2060-2068
155. Assassi S, Mayes MD, McNearney T, Fischbach M, Reveille JD, Arnett FC, Tan FK. Polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in systemic sclerosis. *Am J Med.* 2005; 118: 907-11.
 156. Ward MM, Weisman MH, Davis JC, Reveille JD. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. *Arthritis Rheum.* 2005 ; 53: 710-717.
 157. Calvo-Alen J, McGwin Jr G, Toloza SM, Fernandez M, Roseman JM, Bastian HM, Cepeda EJ, Gonzalez EB, Baethage BA, Fessler BJ, Vila LM, Reveille JD, Alarcon GS. Systemic Lupus Erythematosus in a Multiethnic US Cohort (LUMINA) XXIV: Cytotoxic Therapy is an Additional Risk Factor for the Development of Symptomatic Osteonecrosis in Lupus Patients. Results of a Nested Matched Case-Control Study. *Ann Rheum Dis.* 2005 Nov 10; [Epub ahead of print]
 158. Alarcon GS, Beasley TM, Roseman JM, McGwin G Jr, Fessler BJ, Bastian HM, Vila LM, Tan F, Reveille JD. Ethnic disparities in health and disease: the need to account for ancestral admixture when estimating the genetic contribution to both (LUMINA XXVI). *Lupus.* 2005;14(10):867-8.
 159. Vila LM, Alarcon GS, McGwin G Jr, Bastian HM, Fessler BJ, Reveille JD. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. *J Rheumatol.* 2005 Nov;32(11):2150-5.
 160. Bertoli AM, Alarcón GS., McGwin G, Fernández M, Bastian HM, Fessler BJ, Vilá LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort. LUMINA XXVII. Factors predictive of a decline to low levels of disease activity. *Lupus* 2006; 15: 13-18
 161. Bertoli AM, Fernández M, Calvo-Alen J, Vilá LM, Sanchez ML, Reveille JD, Alarcón GS. Systemic lupus erythematosus in a multiethnic US cohort. LUMINA XXXI. Factors predictive of a patients being lost to followup. *Lupus* 2006; 15: 19-25.
 162. O'Hanlon TP, Mercatante-Carrick D, Arnett FC, Reveille JD, Carrington M, Oddis CV, Morel P, Malley JD, Malley K, Dreyfuss J, Shamim E, Rider LG, Chanock SJ, Foster C, Bunch T, P, Miller FW. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic distinguish European-American patients with different myositis antibodies. *Medicine (Baltimore).* 2006; 85:111-127.
 163. Bertoli AM, Fernández M, McGwin G, Alarcón GS, Tan FK, Reveille JD, Vilá LM. Systemic lupus erythematosus in a multiethnic US cohort. LUMINA XXXVI. Influence of mannose-binding lectin exon 1 polymorphisms in disease manifestations, course and outcome. *Arthritis Rheum* 2006; 54: 1703-04.
 164. Calvo-Alen J, Alarcón GS, Tew MB, Tan FK, McGwin G Jr, Fessler BJ, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort: XXXIV. Deficient mannose-binding lectin exon 1 polymorphisms are associated with cerebrovascular but not with other arterial thrombotic events. *Arthritis Rheum.* 2006; 54:1940-1945

165. Bertoli AM, Alarcón GS, Calvo-Alen J, Fernández M, Vilá LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort. Clinical features, course and outcome in patients with late onset disease. *Arthritis Rheum* 2006; 54: 1580-87.
166. Bertoli AM, Fernandez M, McGwin G Jr, Reveille JD, Alarcón GS. Association of antioxidantized low-density lipoprotein antibodies with vascular arterial events and renal manifestations in systemic lupus erythematosus patients: Comment on the article by Frostegard et al. *Arthritis Rheum*. 2006; 54: 2035-2036
167. Alarcón GS, Calvo-Alen J, McGwin G, Uribe AG, Toloza SM, Roseman JM, Fernandez M, Fessler BJ, Vila LM, Ahn C, Tan F, Reveille JD. Systemic lupus erythematosus in a multiethnic cohort. LUMINA. XXXV. Predictive factors of high disease activity over time. *Ann Rheum Dis* 2006; 65:1168-74.
168. Basu D, Williams FM, Ahn CW, Reveille JD. The Changing Spectrum Of Diffuse Infiltrative Lymphocytosis Syndrome. *Arthritis Rheum* 2006; 54: 466-472
169. Berrios-Rivera JP, RL, Popa-Lisseanu MGG, Kallen MA, Richardson MN, Janssen NM, Marcus DM, Reveille JD, Warner NB, Suarez-Almazor ME, Trust in Physicians and Elements of the Medical Interaction in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus. *Arthritis Rheum*, 2006; 55: 385-393.
170. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, placebo-controlled trial. *Arthritis Rheum* 2006; 54: 2136-2146.
171. Bertoli AM, Fernandez M, Alarcon GS, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic U.S. cohort LUMINA (XLI): Factors predictive of self-reported work disability. *Ann Rheum Dis*. 2007;66:12-7.
172. Andrade RM, McGwin G Jr, Alarcon GS, Sanchez ML, Bertoli AM, Fernandez M, Fessler BJ, Apte M, Arango AM, Bastian HM, Vila LM, Reveille JD. Predictors of post-partum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII). *Rheumatology (Oxford)*; 2006 45: 1380-4.
173. Ward MM, Bruckel J, Colbert R, Doedhar A, Emerson C, Genant H, Gladman DD, Inman R, Reveille JD, Sandborg C, Weisman MH, Davis JC Jr. Summary of the 2005 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). *J Rheumatol*. 2006 May;33(5):978-82.
174. Vila LM, Alarcon GS, McGwin G Jr, Bastian HM, Fessler BJ, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: Association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. *Arthritis Rheum*. 2006 Sep 29;55(5):799-806
175. O'Hanlon TP, Rider LG, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, Miller FW. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. *Arthritis Rheum*. 2006 Oct 30;54(11):3670-3681.
176. Alarcón GS, McGwin G, Petri M, Ramsey-Goldman R, Fessler BJ, Vilá LM, Reveille JD, Kimberly RP. Time to renal disease and end stage renal disease in PROFILE: A multiethnic lupus cohort. *PLoS Medicine* 2006; 3: 1949-1956.

177. Fernandez M, McGwin G, Bertoli AM, Calvo-Alen J, Vila LM, Reveille JD, Alarcón GS. Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multi-ethnic US cohort (LUMINA XL). *Lupus* 2006; 15: 700-704.
178. Chaiamnuay S, Bertoli AM, Roseman JM, McGwin G, Apte M, Vila LM, Duran S, Reveille JD, Alarcón GS. African American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: Results from LUMINA, a multiethnic cohort (LUMINA XLV). *Ann Rheum Dis* 2006; Nov 15 (Epub).
179. Bastian HM, Alarcón GS, Roseman JM, McGwin G, Vilá LM, Fessler BJ, Reveille JD. Systemic lupus erythematosus in a multiethnic U.S. cohort (LUMINA): Factors predictive of new or worsening proteinuria. *Rheumatology (Oxford)*. 2007 Apr;46(4):683-9.
180. Lee W, Reveille JD, Davis JC, Leach TJ, Ward MM, Weisman MH. Are there Gender differences in the severity of ankylosing spondylitis: results from the PSOAS cohort. *Ann Rheum Dis* 2007 May;66(5):633-8..
181. Tsui HW, Inman RD, Reveille JD, Tsui FW. Association of a TNAP haplotype with ankylosing spondylitis. *Arthritis Rheum*. 2007; 56: 234-243
182. Fernandez M, Alarcón GS, Apte M, Andrade RM, Vilá LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort XLIII. The significance of thrombocytopenia as a prognostic factor. *Arthritis Rheum* 2007; 56: 614-621.
183. Andrade RM, Alarcón GS, Fernández M, Apte M, Vilá LM, Reveille JD. Accelerated damage accrual among men with systemic lupus erythematosus. XLIV. Results from a multiethnic US cohort. *Arthritis Rheum* 2007; 56 : 622-630.
184. McNearney TA, Reveille JD, Fischbach M, Freidman AW, Lisse JR, Goel N, Tan FK, Ahn C, Feghali-Bostwick CA, Fritzler M, Arnett FC, Mayes MD. Pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic and behavioral factors. *Arthritis Rheum* 2007; 57: 318-326.
185. Carter KW, Pluzhnikov A, Timms AE, Miceli-Richard C, Jin L, Wordsworth BP, Cox NJ, Palmer LJ, Breban M, Reveille JD, Brown MA. Meta-analysis of three whole genome linkage scans for ankylosing spondylitis. *Rheumatology (Oxford)*, 2007; 46(5):763-71
186. Alarcon GS, McGwin G Jr, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, Vilá LM, Reveille JD. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. data from LUMINA , a multiethnic us cohort (LUMINA L).*Ann Rheum Dis*. 2007 Sep;66(9):1168-72.
187. Khan MA, Clegg DO, Deodhar AA, Gabriel S, Gaston JS, Hirsch R, Reveille JD, Turkiewicz AM, Weisman MH, Davis JC Jr, Ostergaard M. 2006 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). *J Rheumatol*. 2007; 34:1118-24.
188. Fernandez M, Alarcón GS, Calvo-Alen J, Andrade R, McGwin G Jr, Vilá LM, Reveille JD, A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. *Arthritis Rheum*. 2007 30; 57: 576-584.
189. Assassi S, Arnett FC, Reveille JD, Gourh P, Mayes MD. Clinical, immunologic, and genetic features of systemic sclerosis. *Arthritis Rheum* 2007; 56: 2031-2037

190. Chaiamnuay S, Bertoli AM, Fernandez M, Apte M, Vilá LM, Reveille JD, Alarcón GS. The impact of increased body mass on systemic lupus erythematosus. Data from LUMINA, a multiethnic cohort. *J Clin Rheumatol* 2007; 13: 128-133.
191. Gladman DD, Inman RD, Cook RJ, van der Heijde D, Landewé RB, Braun J, Davis JC, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, Maksymowych WP.. International Spondyloarthritis Interobserver Reliability Exercise - The INSPIRE Study: I. Assessment of Spinal Measures. *J Rheumatol.* 2007; 34(8):1733-9.
192. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, Landewé RB, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O'Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, van der Heijde D. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. *J Rheumatol.* 2007 Aug;34(8):1740-5.
193. Bertoli AM, Vilá LM, Apte M, Fessler BJ, Bastian HM, Reveille JD, Alarcón GS; Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual. *Rheumatology (Oxford).* 2007 46(9):1471-6.
194. Bertoli AM, Alarcón GS, McGwin G Jr, Sanchez ML, Apte M, Vilá LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVII: factors predictive of pulmonary damage. *Lupus* 2007; 16: 410-417.
195. Fernandez M, Alarcón GS, Vilá LM, Reveille JD. Reply. *Arthritis Rheum* 2007; 56: 2812.
196. Fernandez M, Alarcón GS, McGwin G Jr, Sanchez ML, Apte M, Vilá LM, Reveille JD. Using the short form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus. XLVII, results from a multiethnic US cohort. *Arthritis Rheum* 2007; 57: 986-992.
197. Fernández M, Calvo-Alén J, Bertoli AM, Bastian HM, Fessler BJ, McGwin G Jr, Reveille JD, Vilá LM, Alarcón GS. Systemic Lupus Erythematosus in a Multiethnic US Cohort (LUMINA L II): Relationship Between Vascular Events and the Use of Hormone Replacement Therapy in Postmenopausal Women. *J Clin Rheumatol.* 2007; 13: 261-265.
198. Bertoli AM, Vilá LM, Reveille JD, Alarcón GS. Systemic Lupus Erythematosus in a multiethnic US cohort (LUMINA): Disease expression and outcome in acute-onset lupus. *Ann Rheum Dis.* 2007 Aug 24; [Epub ahead of print].
199. WTCCC and TASC* (**Reveille JD**, Zhou X, Bradbury LA, Sims AM, Dowling A, Taylor J, Doan T, Cardon LR, Davis JC, Pointon JJ, Savage L, Ward MM, Leach TL, Weisman MH, Wordsworth BP, Brown MA. Association scan of 14,500 nsSNPs in four common diseases identifies variants involved in autoimmunity. *Nature Genetics,* 2007;39:1329-37.
200. Barahmani N, de Andrade M, Slusser JP, Wei Q, Hordinsky M, Price VH, Christiano A, Norris D, Reveille J, Duvic M. Human Leukocyte Antigen Class II alleles are associated with risk of alopecia areata. *J Invest Dermatol.* 2008 Jan;128(1):240-3.
201. Sims AM, Timms AE, Bruges-Armas J, Chou CT, Doan T, Dowling A, Fialho RN, Gergely P, Gladman DD, Inman R, Kauppi M, Kaarela K, Laiho K, Maksymowych

- W, Rahman P, Reveille JD, Tuomilehto J, Wordsworth BP, Xu H, Brown MA. Prospective meta-analysis of IL-1 gene complex polymorphisms confirms associations with ankylosing spondylitis. *Ann Rheum Dis*. 2007 Dec 6; [Epub ahead of print]
202. Cepeda EJ, Williams FM, Ishimori M, Weisman MH, Reveille JD. The Use of Anti-Tumor Necrosis Factor Therapy in HIV Positive Individuals with Rheumatic Disease. *Ann Rheum Dis*, 2007; [Epub ahead of print].
203. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH. Estimates of the Prevalence of Arthritis and Other Rheumatic Conditions in the United States I. *Arthritis Rheum* 2008 Jan;58(1):15-25.
204. Edberg JC, Wu J, Langefeld CD, Brown EE, Marion MC, McGwin G, Petri M, Ramsey-Goldman R, Reveille JD, Frank SG, Kaufman KM, Harley JB, Alarcón GS, Kimberly RP. Genetic Variation in the CRP Promoter: Association with Systemic Lupus Erythematosus (SLE). *Hum Mol Genet*. 2008 Jan 8; [Epub ahead of print]
205. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, Cox V, Kallen MA, Janssen N, Ng B, Marcus DM, Reveille JD, Suarez-Almazor ME. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. *Clin Rheumatol*. 2008 Jan 8; [Epub ahead of print]
206. González LA, McGwin G Jr, Durán S, Pons-Estel GJ, Apte M, Vilá LM, Reveille JD, Alarcón GS. Predictors of Premature Gonadal Failure in Patients with Systemic Lupus Erythematosus. Results from LUMINA, a Multiethnic US Cohort. *Ann Rheum Dis*. 2008 Jan 16; [Epub ahead of print]
207. Apte M, McGwin G Jr, Vilá LM, Kaslow RA, Alarcón GS, Reveille JD. Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort. *Rheumatology (Oxford)*. 2008 Feb 4;
208. Ramsey-Goldman R, Alarcón GS, McGwin G, Petri M, Vilá LM, Edberg JC, Reveille JD, Kimberly RP. Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort. *Lupus* 2008; in press
209. Kelly JA, Kelley JM, Kaufman KM, Kilpatrick J, Bruner GR, Merrill JT, James JA, Frank SG, Reams E, Brown EE, Gibson AW, Marion MC, Langefeld CD, Li QZ, Karp DR, Wakeland EK, Petri M, Ramsey-Goldman R, Reveille JD, Vilá LM, Alarcón GS, Kimberly RP, Harley JB, Edberg JC. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. *Genes Immun*. 2008 Feb 21 [Epub ahead of print]
210. Gensler L, Ward MM, Reveille JD, Weisman MH, Davis JC Jr. Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. *Ann Rheum Dis*. *Ann Rheum Dis*. 2008 Feb;67(2):233-7.
211. Lee W, Reveille JD, Weisman MH. Women with ankylosing spondylitis: A review. *Arthritis Rheum*. 2008 Feb 29;59(3):449-454

INVITED ARTICLES

1. McDaniel DO, Barger BO, Reveille JD, Alarcón GS, Koopman WJ, Acton RT: Analysis of restriction fragment length polymorphisms in rheumatic diseases. *Rheum Dis Clin* 13:353-367, 1987.

2. Reveille JD: The impact of race in SLE. *Lupus News* 9:4-5, 1989.
3. Reveille JD: Systemic lupus erythematosus. Part I: A clinical and diagnostic challenge. *The Female Patient* 1990; 15: 41-48.
4. Reveille JD: Systemic lupus erythematosus. Part II: Issues in long term management and pregnancy. *The Female Patient* 1990; 15: 21-28.
5. Reveille JD: Molecular genetics of systemic lupus erythematosus and Sjögren's syndrome. *Current Opin Rheumatol* 1990; 2: 733-739.
6. Arnett FC, Reveille JD, Duvic M: Psoriasis and psoriatic arthritis associated with human immunodeficiency virus (HIV) infection. *Rheum Dis Clin* 1991; 17: 59-78.
7. Reveille JD, Arnett FC: Immunogenetics of systemic autoimmune disease. *Immunol Ser* 1991; 54: 97-104.
8. Reveille JD: The molecular genetics of systemic lupus erythematosus and Sjögren's syndrome. *Current Opin Rheumatol* 1991; 3:722-730.
9. Reveille JD, Arnett FC: The immunogenetics of Sjögren's syndrome. *Rheum Dis Clin* 1992; 18: 539-550.
10. Reveille JD: Advances in the care of lupus patients. *Hospital Practice* 8:80-93, 1992.
11. Arnett FC, Reveille JD: Genetics of systemic lupus erythematosus. *Rheum Dis Cl N Amer* 1992; 18: 865-892.
12. Reveille JD: The molecular genetics of systemic lupus erythematosus and Sjögren's syndrome 1992. *Current Opin Rheum* 1992; 4:644-656.
13. Reveille JD: The interplay of nature vs nurture in predisposition to the rheumatic diseases. *Rheum Dis Cl N Amer* 1993; 19: 15-27.
14. Reveille JD: The molecular genetics of systemic sclerosis. *Current Opin Rheumatol* 1993; 5:753-759.
15. Reveille JD: The molecular genetics of systemic sclerosis. *Current Opin Rheumatol* 7:522-528, 1995.
16. Reveille JD: Soft-tissue rheumatism: Diagnosis and treatment. *Amer J Med*, 102:23-29, 1997.
17. Reveille JD: The genetic contribution to the pathogenesis of rheumatoid arthritis. *Current Opin Rheumatol* 10: 187-200, 1998.
18. Al-Khonizy W, Reveille JD. The immunogenetics of the seronegative spondyloarthropathies. *Baillieres Clin Rheumatol* 1998; 12: 567-588.
19. Reveille JD: HLA-B27 and the seronegative spondyloarthropathies. *Am J Med Sci* 1998; 316:239-249
20. Reveille JD, Moulds JM, Ahn C, Friedman A, Baegthe B, Roseman MD, Straaton K, Alarcón G: Systemic lupus erythematosus in three ethnic groups I: The effects of HLA-class II, C4 and CR1 alleles, socioeconomic factors and ethnicity at disease onset. *BioMedicina* 2:473-480, 1999.
21. Alarcón GS, Brooks K, Reveille JD, Lisse JR: Do patients of Hispanic and African-American ethnicity with LUPUS experience worse outcomes than patients with lupus from other populations? The LUMINA Study. (Letter) *Lupus News* 1999; 2:4-5
22. Reveille JD: The genetics of ankylosing spondylitis. *Bull Rheum Dis* 50:2-3, 2001.
23. Reveille JD, Ball EJ, Khan MA. HLA-B27 and genetic predisposing factors in spondyloarthropathies. *Curr Opin Rheumatol*. 2001; 13: 265-72.
24. Brown MA, Wordsworth BP, Reveille JD. Genetics of ankylosing spondylitis. *Clin Exp Rheumatol*. 2002; 20(6 Suppl 28):S43-9.

25. Reveille JD: Ethnicity/race and SSc-how it affects susceptibility, severity, antibodies genetics and clinical manifestations. *Curr. Rheum Rep* 2003; 5: 160-7.
26. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. *Arthritis Res Ther.* 2003; 5: 80-93.
27. Mody GM, Parke FA, Reveille JD. Articular manifestations of human immunodeficiency virus infection. *Best Pract Res Clin Rheumatol.* 2003;17: 265-87.
28. Reveille JD: Lupus Awareness in Minorities: New Knowledge, New Challenges. *Lupus News:* 2003; In press.
29. Reveille JD: The genetic basis of spondyloarthritis. *Current Rheumatology Rep* 2004; 6:117-25.
30. Uribe AG, McGwin G, Reveille JD, Alarcón GS. What have we learned from a ten-year experience With the LUMINA cohort? Where are we heading? *Autoimmunity Reviews,* 2004; 3: 321-9..
31. Reveille JD: Predictive value of autoantibodies for activity of systemic lupus erythematosus. *Lupus* 2004; 13: 1-8.
32. Reveille JD: HIV-1 infection and the rheumatic diseases: New Issues, New Challenges, Same Old Disparities. *AIDS Read.* 2004;14:178-9.
33. Reveille JD. Genetic studies in the rheumatic diseases: The present status and implications for the future. *J Rheumatol suppl.* 2005;72:10-13.
34. Fernández M, Calvo-Alén J, Li Q, McGwin GJr, Vilá LM, Reveille JD. LUMINA, una cohorte de pacientes con lupus en minorías étnicas de Estados Unidos. ¿Qué hemos aprendido? LUMINA, a multiethnic US lupus cohort what have we learned? *Vital Academia Biomedica Digital.* 2004; In press.
35. Cepeda EJ and Reveille JD: Autoantibodies in systemic sclerosis and fibrosing syndromes: Clinical indications and relevance. *Current Opin Rheumatol.* 2004; 16: 723-32.
36. Basu D, Reveille JD. Autoantibody determination in the autoimmune rheumatic syndromes-anti-Scl-70. *Autoimmunity* 2005; 38:65-72.
37. Reveille JD, Arnett FC: Spondyloarthritis: Update on Pathogenesis and Treatment. *Am J Med* 2005 118: 592-603.
38. Reveille, JD. Spondyloarthritis (Spondyloarthropathies). *Patient Education Facts.* http://www.theacr.org/public/factsheets/spondylitis_new.asp, June, 2005.
39. Reveille JD. MHC genes and ankylosing spondylitis susceptibility. *Best Pract Res Clin Rheumatol* 2006; 20: 601-9..
40. Arango AM, Reveille JD. The treatment of SLE. *Women's Health,* In press, 2006
41. Reveille, JD. The genetic basis of ankylosing spondylitis. *Current Opin Rheumatol* 2006; 18: 332-41.
42. Reveille JD and Williams FM. Current issues in rheumatic disease complications of HIV infection. *Best Pract Res Clin Rheumatol* 2006; 20: 1159-1179.
43. Reveille JD. The genetic basis of autoantibody production. *Autoimmun Rev.* 2006; 5: 389-98.
44. Maganti RM, Williams FM, Reveille JD. The changing face of rheumatic disease in HIV infection. *Nature Rheumatology* 2008 (in press)
45. Briones TA, Reveille JD. The contribution of genes outside the major histocompatibility complex to susceptibility to ankylosing spondylitis. *Current Opin Rheumatol* 2008 (in press)

46. Maganti RM, Reveille, JD. Subtypes of HLA-B27: History and implications in the pathogenesis of ankylosing spondylitis In press.

BOOK CHAPTERS

- 1) Reveille JD: The Spondyloarthropathies, in Clinical Rheumatology, Ball, G.V., Koopman, W.J., eds. W.B. Saunders Co., Philadelphia, pp 164-182, 1986.
- 2) Reveille JD: Immunogenetics, in Rheumatology and Immunology, Cohen, A.S., Bennett, J.C., eds., Grune & Stratton, Inc., Orlando, pp 426-433, 1986.
- 3) Reveille JD, Arnett FC: Immunogenetics of systemic autoimmune diseases, in Systemic Autoimmunity. Edited by P. Bigazzi and M. Reichlin, Marcel-Dekker, Inc. pp 97-140, 1991.
- 4) Reveille JD: The organization of the major histocompatibility complex, in Advanced Immunoassays in Rheumatology. Edited by M Teodorescu and C Froelich, CRC Press, Inc., Boca Raton, FL, pp 283-301, 1994.
- 5) Reveille JD: DNA typing for MHC alleles, in Advanced Immunoassays in Rheumatology. Edited by M Teodorescu and C Froelich, CRC Press, Inc., Boca Raton, FL, pp 319-330, 1994.
- 6) Reveille JD: MHC genes and disease susceptibility, in Advanced Immunoassays in Rheumatology. Edited by M Teodorescu and C Froelich, CRC Press, Inc., Boca Raton, FL, pp 331-365, 1994.
- 7) Reveille JD: MHC Class II And Non-MHC Genes In The Pathogenesis Of Systemic Lupus Erythematosus. In; Lahita RG, ed. Systemic Lupus Erythematosus. Third Edition San Diego: Academic Press, p67, 1999.
- 8) Reveille JD: HIV and the Rheumatic Diseases, in Kelley's Textbook of Rheumatology , 6th Edition, S. Ruddy, ED Harris, CB Sledge, Eds. WB Saunders, Philadelphia, p. 1507, 2001.
- 9) Reveille JD: The Treatment of Systemic Lupus Erythematosus. In, Arthritis and Allied Conditions , 14th Edition, WJ Koopman, Ed, Lippincott William & Wilkins, Philadelphia, PA; Chapter 76, pp1533-1545, 2001.
- 10) Reveille JD: The Seronegative Spondyloarthropathies: Epidemiology, Pathology And Pathogenesis: in The Primer for the Rheumatic Diseases; Klippel JH, ed. Srthritis Foundation, Atlanta, p 239, 2001.
- 11) Reveille JD: MHC Class II And Non-MHC Genes In The Pathogenesis Of Systemic Lupus Erythematosus. In; Lahita RG, ed. Systemic Lupus Erythematosus. Fourth Edition, San Diego: Academic Press, 2003.
- 12) Mayes MD and Reveille JD: Epidemiology, Demographics, and Genetics. In. Systemic Sclerosis- Clements P and Furst DE eds 2nd edition. Philadelphia, Lippincott, Williams and Wilkins, 2004., .
- 13) Reveille JD: HIV and the Rheumatic Diseases, in Kelley's Textbook of Rheumatology , 7th Edition, S. Ruddy, ED Harris, CB Sledge, Eds. WB Saunders, Philadelphia, 2005.
- 14) Reveille JD and Brown MA. The Pathogenesis Of Ankylosing Spondylitis in Ankylosing Spondylitis; Weisman MH, van der Heijde D, Reveille JD eds. Elsevier, New York, in press.
- 15) Reveille JD and Alkassab F. Reactive Arthritis in Reactive Arthritis and Psoriatic Arthritis; Ritchlin C ed. Elsevier, New York, in press.
- 16) Reveille JD and Maganti R: HIV and the Rheumatic Diseases, in Kelley's Textbook of Rheumatology , 7th Edition, S. Ruddy, ED Harris, CB Sledge, Eds. WB Saunders, Philadelphia, 2007.

INVITED LECTURESHIPS

1. The Immunogenetics of Systemic Lupus Erythematosus, given at the Lowe Southeastern Rheumatology Conference, Alexander City, AL, September, 1983.
2. Rheumatic Diseases in the Elderly, given at the University of Alabama Center for Aging, Birmingham, Alabama, July 1986.
3. The Immunogenetics of the Seronegative Spondyloarthropathies, given at the Annual Meeting of the Asociación Peruana de Reumatología, Lima, Peru, September, 1987.
4. Clinical Features of the Seronegative Spondyloarthropathies, given at the Annual Meeting of the Asociación Peruana de Reumatología, Lima, Peru, September, 1987.
5. Restriction Fragment Length Polymorphism Analysis in Ankylosing Spondylitis, given at the Workshop on the Immunogenetics of the Rheumatic Diseases, NIAMS, Bethesda, Maryland, June 1988.
6. Rheumatic Diseases in the Elderly, given at the University of Alabama Center for Aging, Birmingham, Alabama, July 1988.
7. Restriction Fragment Length Polymorphisms of MHC Genes in Sjögren's Syndrome, given at 2nd International Symposium on Sjögren's Syndrome, Austin, TX, October, 1988.
8. The Molecular Genetics of Ankylosing Spondylitis, given at the Virginia Rheumatism Association Annual Meeting, Virginia Beach, VA, October 1988.
9. The Clinical and Treatment Issues in Systemic Lupus Erythematosus, given at Medical Grand Rounds, Heights Hospital, Houston, Texas, March 1989.
10. The Immunogenetics of Rheumatic Diseases, given at the Antibody Club, Blood Center, Houston, Texas, May 1989.
11. The Seronegative Spondyloarthropathies, given at Medical Grand Rounds, The University of Texas Medical Branch, Galveston, TX, June, 1989.
12. Rheumatic Diseases in the Elderly, given at the University of Alabama Center for Aging, Birmingham, Alabama, July 1989.
13. The Approach to Polyarthritis, given at the University of Texas Medical Branch, Galveston, Texas, October 1989.
14. Rheumatic Diseases of the Elderly, given at the University of Alabama Center for Aging, Birmingham, Alabama, July, 1990.
15. The Immunogenetics of Sjögren's Syndrome, given at the Sjögren's Study Group, American College of Rheumatology Meetings, Seattle, WA, October, 1990.
16. HIV Infection and the Rheumatic Diseases, given at Medical Grand Rounds, The University of Texas at San Antonio, San Antonio, TX, December 1990.
17. HIV Infection and the Rheumatic Diseases, given at the Maryland Society for the Rheumatic Diseases, Baltimore, Maryland, May 1991.
18. The Molecular Genetics of Systemic Sclerosis, given at Rheumatology Grand Rounds, The Johns Hopkins University School of Medicine, Baltimore, Maryland, May 1991.
19. The Immunogenetics of Scleroderma, given Rheumatology Grand Rounds, The University of Miami School of Medicine, Miami, Florida, May 1991.
20. Rheumatic Diseases in the Elderly, given at the University of Alabama Center for Aging, Birmingham, Alabama, July 1991.
21. Lupus and Genetics, given at 19th Annual State Symposium, Oklahoma Lupus Association, Oklahoma City, Oklahoma, April 1992.

22. The Genetic Basis of Systemic Lupus Erythematosus, given at the Third International Conference on SLE, London, England, April 1992.
23. Infection and the Rheumatic Diseases, given at Louisiana State University Conference, New Orleans, Louisiana, May 1992.
24. Management of Arthritis in the 1990's: Infection & Arthritis, given for University of South Florida at Boca Raton, Florida, June 1992.
25. The Immunogenetics of Systemic Lupus Erythematosus, given at the Lupus Study Group of the American College of Rheumatology, Atlanta, Georgia, October 1992.
26. The Molecular Genetics of the Seronegative Spondyloarthropathies, given at the Spondylitis Study Group, American College of Rheumatology, Atlanta, Georgia, October 1992.
27. Clinical Serologic & Immunogenetic Features of Scleroderma, given at SUNY-Downstate Medical Center, New York City, November 1992.
28. MHC Class II alleles and the Rheumatic Diseases, given at Temple University, Philadelphia, Pennsylvania, November 1992.
29. The Structure & Role of HLA-B27 in the Pathogenesis of Seronegative Spondyloarthropathies, given at the Mexican Society of Rheumatology, Mexico City, Mexico, January 1993.
30. Around the World with HLA, given at New York University Medical Center, New York, NY, March, 1993. Newark, New Jersey, March 1993.
31. The Molecular Genetics of Systemic Sclerosis, given at Temple University, Philadelphia, Pennsylvania, June 1993.
32. The Immunogenetics of the Rheumatic Diseases, given at the Institute of Rheumatology of the Russian Academy of Science, Moscow, Russia, July 1993.
33. Molecular Genetics and Autoantibody Subsets of Systemic Sclerosis, given at the XVIII ILAR Congress of Rheumatology, Barcelona, Spain, July 1993.
34. The Future Role of Genetics in the Rheumatic Diseases, given at University of Medicine & Dentistry of New Jersey, New Jersey Medical School, Secaucus, New Jersey, October 1993.
35. The Immunogenetics of the Rheumatic Diseases, given at Grand Rounds, Wilford Hall, USAF Medical Center, San Antonio, Texas, October 1993.
36. The Immune Response and Scleroderma: Immunogenetics, given at the International Conference on Scleroderma, Sydney, Australia, February 1994.
37. HLA Class II Associations with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Scleroderma: A Worldwide Perspective, given at the Annual Meeting of the Japanese Rheumatism Association, Tokyo, Japan, May 1994.
38. The Immunogenetics of the Rheumatic Diseases, given at the Asociación Peruana de Reumatología, Cuzco, Peru, September 1994.
39. The Course and Outcome of Systemic Lupus Erythematosus, given at the Asociación Peruana de Reumatología, Cuzco, Peru, September 1994.
40. Rheumatic Diseases in the Pima Indians: Progress and Opportunities workshop, given at the Phoenix Epidemiology and Clinical Research Branch, NIAMS, Phoenix, Arizona, March 30, 1995.
41. Genetic Predisposition to Lupus in African-Americans given at the Lupus Foundation Symposium, Houston, Texas, October 1995.
42. Research - Hope for the Future given at the Spondylitis Association of America Annual

- Patient and Family Forum, San Francisco, California, October 1995.
43. New Developments and Research in Systemic Lupus Erythematosus given at the American College of Rheumatology National Meeting, San Francisco, California, October 1995.
 44. Laboratory Testing & the Arthritis Patient: Questions and Answers given at the Winter Arthritis Symposium at Plains Baptist Hospital in Amarillo, Texas, November 1995.
 45. Soft Tissue Rheumatism: Diagnosis and Treatment given for the Albert Einstein College of Medicine/Montefiore Medical Center Office of Continuing Medical Education, Houston, Texas, November 1995.
 46. Joint Aspiration and Injection workshop given at the Department of Family Practice and Community Medicine, Hermann/LBJ Residency Program, Houston, Texas, November 1995.
 47. Systemic Lupus Erythematosus given at the Department of Family Practice and Community Medicine, Hermann/LBJ Residency Program, Houston, Texas, November 1995.
 48. Genetics and Outcome in Systemic Lupus Erythematosus, IX Peruvian Rheumatology Congress, Asociación Peruana de Reumatología Lima, Peru, Nov. 21-23, 1996.
 49. Ethnicity and Rheumatic Disease Outcomes given at the Outcomes Research Forum, Houston, Texas, February 6, 1997
 50. Soft Tissue Rheumatism given at the Hermann/LBJ Family Practice Residency Program, Houston, Texas, May 7, 1997.
 51. Lupus lecture given at the Department of Family Practice and Community Medicine, Houston, Texas, May 28, 1997.
 52. Factors affecting Outcome in Systemic Sclerosis: The University of Texas, School of Public Health, October 9, 1997.
 53. The contribution of ethnicity to outcome in SLE in three ethnic groups given at the Johns Hopkins University, November 7, 1997.
 54. The diffuse infiltrative lymphocytosis syndrome and HIV associated muscle disease given at the Arthritis Foundation - Kansas Chapter, November 21, 1997.
 55. Lupus and Seizures given at the CPC at The University of Texas Medical School - Houston, February 2, 1998.
 56. The effect of Nature vs. Nurture on outcome in SLE given at the TMC at The University of Texas Medical School-Houston, February 3, 1998.
 57. Interaction of HLA genes and environment in SLE given to the Medicine Grand Rounds at The University of Texas Health Science Center at San Antonio, April 15, 1998.
 58. Antinuclear Antibodies 4: Anti-Ro/La to the 32nd College of American Pathologists Conference in Chicago, May 30, 1998.
 59. Clinical and Genetic Aspects of the Seronegative Spondyloarthropathies, Give to the Turkish Rheumatology Association annual meetings, Antalya, Turkey, October 24, 1998.
 60. The Genetics of the Seronegative Spondyloarthropathies, given to the annual meeting of the Australian Rheumatism Association, May, 1999
 61. The Treatment of Difficult Ankylosing Spondylitis, given to the annual meeting of the Australian Rheumatism Association, May, 1999
 62. HIV and the Rheumatic Diseases, given at Medical Grand Rounds, The University of Texas-Houston Health Science Center, January 11, 2000.
 63. Genetic vs. Environmental Factors and Prognosis in Systemic Sclerosis: The GENISOS

- Study given to the Medicine Grand Rounds at The University of Texas-Houston Health Science Center, Houston, TX, April 15, 2000
64. The Genetics of Systemic Sclerosis, given to the International Symposium on Systemic Sclerosis in Vaalsbroek, The Netherlands, Sept. 17, 2000.
 65. An Update on the Seronegative Spondyloarthropathies, Given at the Annual Review Course, Cornell University School of Medicine, New York, NY, Sept 22, 2000.
 66. Family Studies in Ankylosing Spondylitis, given at the Second International Congress on Spondyloarthropathies, Ghent, Belgium, October 6, 2000.
 67. Newer Agents in the Treatment of Rheumatoid Arthritis, given at the annual meeting of the Asociación Peruana de Reumatología, October 13, 2000.
 68. The Genetics of Systemic Sclerosis, given at the annual meeting of the Asociación Peruana de Reumatología, Lima, Peru, October 14, 2000.
 69. The Genetics of Ankylosing Spondylitis given at the annual meeting of the Asociación Peruana de Reumatología, Lima, Peru, October 14, 2000.
 70. The Immunogenetics of Systemic Lupus Erythematosus, given at Boston University School of Medicine, February 27, 2001.
 71. The Genetic Basis of the Seronegative Spondyloarthropathies, given at Boston University School of Medicine, February 28, 2001.
 72. The Genetics of Lupus and Scleroderma: A Unifying Hypothesis, given at the University of Michigan Rheumatology Grand Rounds, March 16, 2001.
 73. The Contribution of Genetics to Predisposition and Prognosis in Systemic Lupus Erythematosus, given at the UT Research Retreat, March 23, 2001.
 74. HIV and the Rheumatic Diseases, given at The University of Pittsburgh Medical Grand Rounds, March 30, 2001.
 75. Genetic and Nongenetic Factors in Predisposition to and Outcome in Systemic Lupus Erythematosus, given at The University of Pittsburgh Rheumatology Grand Rounds, March 30, 2001.
 76. The Genetic Basis of Autoimmunity. The Second Interdisciplinary Symposium on the Treatment of Autoimmune Disorders. The University of Kiel, Kiel, Germany, June 8, 2001.
 77. The Genetic Basis of Ankylosing Spondylitis. EULAR meetings, Prague, Czech Republic, June 15, 2001.
 78. The Immunogenetics of Rheumatoid Arthritis in Indigenous American Populations. The Annual Meeting of the International League Against Rheumatism (ILAR), Edmonton, Alberta, August 28, 2001.
 79. The Immunogenetics of the Seronegative Spondyloarthropathies. Rheumatology Grand Rounds, Hospital for Special Surgery, New York, NY, October 3, 2001.
 80. The Treatment of the Refractory Ankylosing Spondylitis. Breakfast with the Professor, The annual meeting of the American College of Rheumatology, San Francisco, CA, November 14 and 16, 2001
 81. HIV and the Rheumatic Diseases. Viral Arthritis Study Group, The annual meeting of the American College of Rheumatology, San Francisco, CA, November 15, 2001
 82. Factores Genéticas en Artritis Reumatoide. International Symposium on Rheumatology, Caracas, Venezuela, November 24, 2001.
 83. SIDA y Las Enfermedades Reumáticas. International Symposium on Rheumatology, Caracas, Venezuela, November 24, 2001.
 84. The Immunogenetics of the Seronegative Spondyloarthropathies. Rheumatology Grand

- Rounds, Toronto Sick Children's Hospital, Toronto, Ontario, November 27, 2001.
85. The Role of Immunogenetics in General Internal Medicine, the Hugh Little Memorial Lecture, Sunnybrook and Women's College Health Science Centre, Toronto, Ontario, November 27, 2001.
 86. Measures of Joint, Muscle and Renal Involvement in Systemic Sclerosis. Presentation given at the VIII OMERACT meeting, Brisbane, Australia, April 13, 2002.
 87. The Genetic Basis of the Seronegative Spondyloarthropathies. Rheumatology Grand Rounds, UT-Southwestern Medical School, April 18, 2002.
 88. The Immunogenetics of Ankylosing Spondylitis. Rheumatology Grand Rounds, The University of North Carolina-Chapel Hill. May 7, 2002.
 89. HLA and Microsatellite Studies of the Major Histocompatibility Complex in Ankylosing Spondylitis: Given at the Meeting of the XIII International Histocompatibility Workshop, Victoria, Canada, May 13, 2002.
 90. The Immunogenetics of the Seronegative Spondyloarthropathies. Given at the PANLAR meetings, Aruba, June 24, 2002.
 91. The Major Histocompatibility Complex, 2002. Given at the PANLAR meetings, Aruba, June 25, 2002.
 92. MHC Genes in Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic Sclerosis. Given at the PANLAR meetings, Aruba, June 25, 2002.
 93. HLA Genes and the Rheumatic Diseases, given at Medical Grand Rounds, The University of Texas-Houston Health Science Center, July 2, 2002.
 94. Essential Aspects of Fibromyalgia, given at the Houston Youth Leadership Forum, Renaissance Hotel, July 29, 2002.
 95. An Update on Rheumatic Manifestations of HIV Infection, given at the Thomas Street Clinic Weekly Noon Conference, July 30, 2002.
 96. The Genetics of Ankylosing Spondylitis: An Update. Given at the North American Spondylitis Investigators Meeting, New York, NY. August 28, 2002.
 97. The Genetic Basis of the Rheumatic Diseases. Given at the Virginia Rheumatism Association Meeting, Charlottesville, VA, September 29, 2002.
 98. Genetic Studies of MHC and Non-MHC Genes in Familial Ankylosing Spondylitis. Given at the Third International Congress on Spondyloarthropathies, Ghent, Belgium, October 5, 2002.
 99. The Treatment of the Difficult Ankylosing Spondylitis. Breakfast and Lunch with the Professor, The annual meeting of the American College of Rheumatology, New Orleans, LA, October 26 and 29, 2002
 100. Genetic Factors in the Seronegative Spondyloarthropathies: The NASC Experience. Given at the Spondyloarthropathy Study Group. The annual meeting of the American College of Rheumatology, New Orleans, LA, October 26, 2002
 101. New Research Developments in Ankylosing Spondylitis. Given at the Annual Patients' Forum, the Spondylitis Association of America. The annual meeting of the American College of Rheumatology, New Orleans, LA, October 26 and 29, 2002
 102. Preparation of a Guidance Document for the Seronegative Spondyloarthropathies. Given at the Food and Drug Administration, Bethesda, Maryland, October 30, 2002.
 103. Genética Y Su Impacto en el Lupus Eritematoso Sistémico. Given at the Chilean Annual Rheumatology Meetings, Pucón, Chile, November 21, 2002.
 104. Genética Y Su Impacto en el Esclerosis Sistémico. Given at the Chilean Annual

- Rheumatology Meetings, Pucón, Chile, November 22, 2002.
105. Bases Genéticas de las Espondiloartropías. Given at the Chilean Annual Rheumatology Meetings, Pucón, Chile, November 22, 2002.
 106. Guidelines for Prescribing TNF Blockers in Patients with Ankylosing Spondylitis. The ASAS Working Group, Berlin, Germany, January 24th and 25th, 2003.
 107. Improving the Health of Hispanic Women: Lupus. Given at the Health and Human Services/ National Hispanic Medical Association/Congressional Hispanic Caucus Meeting, Washington D.C., January 30, 2003.
 108. Current Issues in the Management and Treatment of The Seronegative Spondyloarthropathies. Given at the San Antonio Rheumatism Association meeting, February 20, 2003.
 109. Ankylosing Spondylitis and the Seronegative Spondyloarthropathies. Department of Medicine Grand Rounds, LSU-Shreveport. February 25, 2003.
 110. Genome-Wide Scans in Ankylosing Spondylitis: The North American Experience. Given at the Genetics of Spondyloarthropathy Symposium, April 8, 2003, Oxford, U.K.
 111. An Update on the Current Management of Ankylosing Spondylitis. Michigan Rheumatism Society Meeting, May 1, 2003.
 112. United States Consensus Guidelines for the Use of Anti-TNF Blockers in Patients with Spondylitis. The ASAS Working Group, San Francisco, CA, June 1st-3rd, 2003.
 113. Current Management of the Seronegative Spondyloarthropathies. Given at the Montana Rheumatism Association Meetings, June 21, 2003
 114. The Genetic Basis of the Rheumatic Diseases. Given at the Montana Rheumatism Association Meetings, June 21, 2003
 115. Workshop on Collaborative Approaches to the Genetics of the Rheumatic Diseases. NIAMS, June 23, and 24th, 2003.
 116. Lupus Nephritis. Given at the Annual National Meeting of the Lupus Foundation of America, Houston, TX July 25th, 2003.
 117. Multicenter Collaborations in Ankylosing Spondylitis: The North American Spondylitis Consortium Experience. Given at the organizational meeting of the Spondyloarthritis Research and Treatment Network, Salt Lake City, August 9, 2003.
 118. Ankylosing Spondylitis and Related Spondyloarthritides: Medical Grand Rounds, Scott and White Medical Center, Temple, TX, August 22, 2003
 119. Race, Ethnicity and Lupus: Given at the Lupus Today Meeting, NIAMS, Washington D.C., September 5, 2003.
 120. The Genetic Basis of the Rheumatic Diseases: Rheumatology Seminar. Given at the University of Tennessee, Memphis, TN, September 9, 2003.
 121. Current Concepts in the Management of the Seronegative Spondyloarthritides: Given at the Memphis Rheumatism Association Meeting, Memphis, TN, September 9, 2003
 122. HIV Infection and the Rheumatic Diseases: Medical Grand Rounds, the University of Tennessee, Memphis, TN, September 10, 2003.
 123. Ankylosing Spondylitis and Related Spondyloarthritides: An Overview. Given at the Symposium “Current Issues in the Seronegative Spondyloarthropathies”, Houston, TX, September 13, 2003.
 124. The Genetics and Pathogenesis the Seronegative Spondyloarthritides: Given at the Symposium “Current Issues in the Seronegative Spondyloarthropathies”, Houston, TX, September 13, 2003.

125. Inflammatory Bowel Disease and Arthritis: Given at the Symposium “Current Issues in the Seronegative Spondyloarthropathies”, Houston, TX, September 13, 2003.
126. The Seronegative Spondyloarthritides: Changing the Paradigm: Medical Grand Rounds, The University of Texas-Houston Health Science Center at Houston, September 30, 2003.
127. Recent Research Breakthroughs in Ankylosing Spondylitis: Given at the annual patient forum of the Spondylitis Association of America, Orlando, FL. October 25th, 2003.
128. An Update on Seronegative Spondyloarthritis: Medical Grand Rounds, Houston Veterans’ Administration Medical Center, Dept. of Medicine. November 10, 2003.
129. Ankylosing Spondylitis and Spondyloarthritis: Grand Rounds, Family Medicine Department, The University of Texas-Houston Health Science Center, November 12, 2003.
130. Musculoskeletal Manifestations of Malignancy: Rheumatology/Radiology Conference, November 19, 2003.
131. Current Issues in the Care of the Patient with Spondyloarthritis: Boulder, Co, December 1, 2003.
132. Spondyloarthritis 2003:Changing the Paradigm. Given for the Rocky Mountain Rheumatism Society, Denver, CO December 1, 2003
133. The Genetics And Pathogenesis Of AS And Other Spondyloarthritides. Rheumatology Conference, the University of Colorado, Denver, CO December 2, 2003.
134. IHWG Disease Component: Project 3: Spondyloarthopathy. Given at NCBI, Bethesda, MD December 10, 2003.
135. Pharmacogenomics and Genetic Studies in AS. Given at the ASAS meetings, Bethesda, MD, January 18, 2004.
136. An Overview of Ankylosing Spondylitis. Given at the Houston Chapter of the Spondylitis Association of America, Jones Museum, Houston, TX, January 28, 2004
137. Autoimmune Disease From Bench To Bedside: Ankylosing Spondylitis. Given at Ohio State University, Columbus, OH, February 2, 2004.
138. The Genetics of the Spondyloarthritides. Given at LSU University, Rheumatology Grand Rounds, February 17, 2004.
139. Spondyloarthritis 2004:Changing the Paradigm. Given at the New Orleans Rheumatism Society, February 17, 2004.
140. Spondyloarthritis 2004. Given for the ARHP Teleconference, February 20, 2004.
141. New Developments in Research in AS and Other Spondyloarthritides. Given at the Oklahoma Medical Research Foundation, February 20, 2004.
142. Clinical Aspects of Spondyloarthritis. The William K. Ishmael Lectureship in Rheumatology at the Oklahoma Medical Research Foundation, February 20, 2004.
143. Lupus and the Clinician: An Overview. Given at the Oklahoma Regional Symposium of the Lupus Foundation of America, Oklahoma City, OK March 19, 2004.
144. An Update in Lupus Nephritis. Given at the Oklahoma Regional Symposium of the Lupus Foundation of America, Oklahoma City, OK March 19, 2004.
145. Ankylosing Spondylitis: An Update On Pathogenesis And Management. Given at Medical Grand Rounds, The University of Maryland, March 31, 2004.
146. The Genetic Basis of Systemic Lupus Erythematosus. Given at Rheumatology Grand Rounds, The University of Maryland, April 1, 2004.
147. Epidemiologic Studies In Spondyloarthritis, given at the joint meeting of the National Arthritis Task Force and the Centers for Disease Control, NIAMS, Bethesda, May 6, 2004.
148. Genetics-The Present And Implications For The Future, given at the Frontiers in

- Inflammation Meetings, Toronto, ON, May 8, 2004.
149. Learning from LUMINA: Overview on Racial Disparities in Lupus. Given at the International Lupus Meetings, New York City, May 11th, 2004.
 150. The Genetic Basis of Systemic Lupus Erythematosus. Given at the International Lupus Meetings, New York City, May 12th, 2004.
 151. Spondyloarthritis: An Update On Pathogenesis And Management. Given at the 5th Convención de la Asociación de Reumatólogos de Puerto Rico, May 29, 2004.
 152. Genetics and Prognosis in Systemic Lupus Erythematosus. Given at the 5th Convención de la Asociación de Reumatólogos de Puerto Rico, May 30, 2004
 153. Pathogenesis of the Spondyloarthropathies. Given at the 2004 Statewide Rheumatology Meeting, Sedona, AZ, June 5, 2004.
 154. The Treatment of the Spondyloarthropathies. Given at the 2004 Statewide Rheumatology Meeting, Sedona, AZ, June 6, 2004.
 155. Diagnosis, Treatment And Prognosis In Ankylosing Spondylitis. Given at the Shanghai Second Medical College, Shanghai, P.R.C., June 28, 2004
 156. The Genetic Basis Of Ankylosing Spondylitis. Given at the Shanghai Second Medical College, Shanghai, P.R.C., June 30, 2004
 157. Spondyloarthritis 2004; Evolving Concepts. Given at Medical Grand Rounds, Oregon Health and Science University, Portland Oregon, July 13, 2004
 158. Nature Vs Nurture: Outcomes in SLE. Given at the Citywide Rheumatology Conference, Portland Oregon, July 13, 2004
 159. The Genetic Basis of Ankylosing Spondylitis. Given at Rheumatology Grand Rounds, Oregon Health and Science University, Portland Oregon, July 14, 2004
 160. How Does Ethnicity Influence the Presentation and Course of Systemic Lupus Erythematosus and Systemic Sclerosis? Given at Medical Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA, July 28, 2004
 161. Update on the Genetics of Spondyloarthritis and the International AS Genetics Consortium. Given at the Second Annual Meeting of the Spondyloarthritis Research and Treatment Network (SPARTAN), Los Angeles, CA. July 31, 2004.
 162. Lupus And Flares: An Overview. Given at the Lupus Foundation of American, Gulf Coast Chapter Symposium, August 14, 2004
 163. An Update on Cytokines in the Pathophysiology and Management of AS. Given at the Fourth Annual Texas Immunology Meetings, Austin, TX. August 21, 2004.
 164. Ethnicity and Prognosis in SLE: The LUMINA Study. Given before the Annual Meeting of the Congressional Black Caucus, Washington, D.C., September 10, 2004.
 165. An Overview on the Genetics of AS and Spondyloarthritis. Given at the IGAS Meeting, Ghent, Belgium, October 7, 2004.
 166. The Genetics of AS-the North American Perspective. Given at the International Spondyloarthritis Meetings, Ghent, Belgium, October 9, 2004.
 167. Ankylosing Spondylitis: An Overview and Recent Research Breakthroughs: Given at the annual patient forum of the Spondylitis Association of America, Orlando, FL. October 16th, 2004.
 168. LUMINA 1994-2004: What Have We Learned? Given at Texas Medical Center Combined Rheumatology Conference, Houston, TX. December 14, 2004
 169. LUMINA 1994-2004: What Have We Learned? Given at Shanghai Second Medical University, Shanghai, China, December 30, 2004.

170. The Pathogenesis of SLE. Given at University of Texas Health Science Center at Houston Annual Research Retreat. Houston, TX, March 5, 2005.
171. Undifferentiated Connective Tissue Disease. Given at the NIH Lupus Consensus Conference, Arlington, VA, May 7, 2005.
172. The Genetic Basis of Ankylosing Spondylitis. Given at the Ankylosing Spondylitis Advisory Board, New York, NY July 30, 2005.
173. SLE 2005- What have We Learned?. Given for the Department of Internal Medicine Grand Rounds, The University of Texas-Houston Health Science Center at Houston, August 9, 2005.
174. An Update on SPARTAN-II. Given for the Spondyloarthritis Research and Treatment Network Annual Meeting, San Francisco, August 13, 2005.
175. An Update on Genetics: NCAM-I and Meta-analysis. Given for the Spondyloarthritis Research and Treatment Network Annual Meeting, San Francisco, August 13, 2005.
176. Spondyloarthritis: An Overview. Given at Family Practice Grand Rounds, Houston, TX. September 14, 2005.
177. The Genetic Basis of Autoantibody Production. Given at the International Symposium on Autoantibodies, Gainesville, FL. October 1, 2005.
178. Genes, History and Disease. Given at Cardiovascular Surgery Grand Rounds, The University of Texas-Houston Health Science Center at Houston, October 14, 2005.
179. Recent Research Breakthroughs in Ankylosing Spondylitis. Given at the annual patient forum of the Spondylitis Association of America, San Diego, CA. November 12th, 2005
180. Interleukin-1 (IL-1) Genes and AS Susceptibility: The North American Experience. Given at the International Genetics of AS (IGAS) Meeting, San Diego, CA, November 16th, 2005.
181. An Update on Ankylosing Spondylitis. Given at Texas Medical Center Combined Rheumatology Conference, Houston, TX. December 13, 2005
182. Genes, History and the Rheumatic Diseases. Given at the Utah Rheumatism Association Annual Meeting, February 4, 2006.
183. Genes, History and Autoimmune Disease. Given at the University of Texas Health Science Center at Houston Medical Grand Rounds, February 28, 2006.
184. New Issues in the Pathophysiology and Treatment of Ankylosing Spondylitis. Given at St. Peter's Hospital Medical Grand Rounds, Missoula, Montana, March 3, 2006
185. Genes, History and Autoimmunity. Given at the University of Montana Graduate School, March 3, 2006.
186. Ankylosing Spondylitis: A Clinical and Genetic Update. Given at the Internal Association of Pain Management Meeting, Berlin, Germany, March 18, 2006.
187. The Genetics of Ankylosing Spondylitis. Given at the symposium "Spondyloarthritis 2006- The Unmet Need", Lister Hill Auditorium, NIH, Bethesda, MD, March 30, 2006.
188. Genes, History and Cardiovascular Disease. Given at Cardiovascular Surgery Grand Rounds, The University of Texas-Houston Health Science Center at Houston, April 14, 2006.
189. Genes, History and Spondyloarthritis. Given at Annual Patient Forum of the Spondylitis Association of America, Houston, TX, April 22, 2006
190. HIV, Hepatitis C and Rheumatic Disease: A Therapeutic Conundrum. Given at the New Mexico Rheumatism Association Meetings, Santa Fe, New Mexico, April 29, 2006
191. Geographic Influences on Flares of Systemic Lupus Erythematosus. Given at the NIH/LFA Conference on the Definition and Validation of Lupus Flares, Washington D.C., May 9, 2006.

192. Genes, History and Autoimmune Disease. Given at Rheumatology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, CA, June 28, 2006.
193. The Epidemiology of Spondyloarthritis: The Present: The NHANES Project. Given for the Spondyloarthritis Research and Treatment Network Annual Meeting, San Francisco, July 29, 2006.
194. Genomics, Proteomics and the Management of the Rheumatic Diseases. Given for the ACR Review Course, Pan American League Against Rheumatism (PANLAR) meetings, Lima, Peru, August 19, 2006.
195. The Treatment of the Difficult Patient with Spondyloarthritis. Given for the Meet the Professor Session, Pan American League Against Rheumatism (PANLAR) meetings, Lima, Peru, August 20, 2006.
196. Recent Advances in the Treatment of Spondyloarthritis. Given for the Pan American League Against Rheumatism (PANLAR) meetings, Lima, Peru, August 21, 2006.
197. The Genetic Basis of the Rheumatic Diseases. Given for Pan American League Against Rheumatism (PANLAR) meetings, Lima, Peru, August 22, 2006.
198. An Update for the Pathogenesis and Treatment of Spondyloarthritis. Given at the University of Texas Health Science Center at Houston Medical Grand Rounds, September 12, 2006.
199. LUMINA 1993-2006-What Have We Learned? Given at the Hispanic Congressional Caucus, Samuel Rayburn Congressional Office Building, October 4, 2006
200. Ankylosing Spondylitis in the 21st Century: Shifting the Paradigm. Given at Medical Grand Rounds, the University of South Florida, Tampa, FL October 5, 2006.
201. Genes, History and Autoimmune Disease. Given at Rheumatology Grand Rounds, New York University, New York, NY October 26, 2006.
202. An Update in Research in AS. Given at the Annual Patient Meeting of the Spondylitis Association of America, Washington D.C., November 11, 2006.
203. Ankylosing Spondylitis: Genetics, Pathogenic Features and Clinical Considerations. Given at the Inflammation and Cardiovascular Disease Symposium and Disease Modification in AS and RA Symposium, Washington D.C., November 12, 2006.
204. HIV Infection and the Rheumatic Diseases. Given at the American College of Rheumatology Annual Meeting, Washington, D.C., November 13, 2006.
205. HIV Infection and the Rheumatic Diseases. Given at the "Meet the Professor" meeting at the American College of Rheumatology Annual Meeting, Washington, D.C., November 15, 2006.
206. History, Genes and Spondyloarthritis. Given at the Australian Pain Symposium, Melbourne, Victoria, Australia, December 2, 2006
207. History, Genes and Spondyloarthritis. Given at the Friends of the Arthritis Center Symposium, Tucson, Arizona, February 15, 2007
208. History, Genes and Autoimmunity. Given at the Tucson Rheumatism Society, Tucson, Arizona, February 15, 2007
209. An Update on the Pathogenesis and Treatment of Spondyloarthritis. Given at the University of Arizona Medical Grand Rounds, Tucson, Arizona, February 16, 2007.
210. Genes, History and the Rheumatic Diseases. Given at the Maryland Society for the Rheumatic Diseases, Baltimore, Maryland. February 20, 2007.
211. An Update on the Pathogenesis and Treatment of Spondyloarthritis. Given at Rheumatology Grand Rounds, Georgetown University, February 21, 2007.
212. Spondyloarthritis 2007: Changing the Paradigm. Given for the DC Rheumatism Society,

- Washington D.C., February 21, 2007.
213. The Evolving Conundrum with HIV Infection In The Rheumatic Diseases. Given at Rheumatology Grand Rounds, George Washington University, Washington D.C., February 22, 2007.
 214. The Genetic Basis of Spondyloarthritis. Given at the UT-Houston School of Public Health, February 26, 2007.
 215. Genes, History and the Autoantibody Response. Given at the International Symposium on the Genetics of Scleroderma, Milan, Italy, March 9, 2007.
 216. Ankylosing Spondylitis and Spondyloarthritis: An Overview. Given at UT Family Practice Grand Rounds, Houston, TX. March 14, 2007.
 217. The Genetic Basis of Spondyloarthritis, Given at the “Update on the Pathogenesis and Management of Low Back Pain” symposium, Cedars Sinai Medical Center, Los Angeles, March 24, 2007
 218. Genes, History and Autoimmunity. Given at the “Update on the Pathogenesis and Management of Low Back Pain” symposium, Cedars Sinai Medical Center, Los Angeles, March 24, 2007
 219. HIV Infection and the Rheumatic Diseases. Given at Medical Grand Rounds, The University of Washington at Seattle, Seattle, WA, April 12, 2007
 220. Genes, History and the Rheumatic Diseases. Given at the Seattle Rheumatism Society, Seattle, WA, April 12, 2007
 221. SLE in Minorities. What We Have Learned From the LUMINA Study, 1993-2007. Given for Rheumatology Grand Rounds, The University of Washington at Seattle, Seattle, WA, April 13, 2007.
 222. The Spectrum and Management of Vasculitis. Given at the Department of Cardiovascular Surgery, April 19, 2007
 223. Ankylosing Spondylitis and Spondyloarthritis: An Overview. Given at Medical Grand Rounds. McGill University, May 08, 2007
 224. Genes, History and the Rheumatic Diseases. Given at the Toronto Rheumatism Society, Toronto, ON, May 08, 2007
 225. SLE in Minorities. What We Have Learned From the LUMINA Study, 1993-2007. Given for Rheumatology Grand Rounds, The University of Toronto, Toronto, ON, May 08, 2007
 226. The Genetic Basis of Spondyloarthritis. Given at the UT-Houston School of Public Health, February 26, 2007.
 227. The Genetic Basis of Spondyloarthritis. Given at the Sao Paolo Rheumatology Meetings, May 26, 2007.
 228. SLE in Minorities. What We Have Learned From the LUMINA Study, 1993-2007. Given at the Sao Paolo Rheumatology Meetings, May 26, 2007.
 229. HIV and the Rheumatic Diseases: An Evolving Conundrum. Given at Medical Grand Rounds, The University of Texas Health Science Center at Houston, May 29, 2007.
 230. History, Genes and Spondyloarthritis. Given at the Annual Patient Meeting of the Spondylitis Association of America, Houston, TX, August 14, 2007
 231. The Epidemiology and Genetics of Spondyloarthritis Given for the Spondyloarthritis Research and Treatment Network Annual Meeting, Cleveland, OH, September 15, 2007.
 232. Genes, Ethnicity and Autoimmunity: A Historical Perspective. given at the Health Disparities Course (HDC), Texas Southern University, October 16, 2007.
 233. Rheumatoid Arthritis and Systemic Lupus Erythematosus. An Update on Pathogenesis and

- Treatment. Given at the SWAHAP, El Paso, Texas, November 2, 2007
234. HIV Infection In The Rheumatic Diseases: A Moving Target. Given at the American College of Rheumatology Annual Meeting, Boston, MA., November 10, 2007.
235. Genes, History and Autoimmunity. Given at the Syracuse Rheumatology Association Meeting, Syracuse, NY, November 15, 2007
236. The Genetic Basis of Spondyloarthritis, Given at Rheumatology Grand Rounds, SUNY Upstate Medical Center, NY, November 16, 2007.
237. Spondyloarthritis. An Update on Pathogenesis and Treatment. Given at Medical Grand Rounds, SUNY Upstate Medical Center, NY, November 16, 2007.
238. Giant Cell Arteritis: Pathogenesis and Management. Given at Neurology Grand Rounds, The University of Texas Health Science Center at Houston, December 7, 2007.
239. Spondyloarthritis: An Update on Pathogenesis and Treatment. Given at Rheumatology Grand Rounds, The University of Virginia, Charlottesville, VA. January 16, 2008.
240. The Genetics of Autoimmunity: A Historical Perspective. Given at the Microbiology and Clinical Immunology conference, The University of Virginia, Charlottesville, VA. January 16, 2008.
241. Ankylosing Spondylitis And Spondyloarthritis: From Bench To Bedside. Given at Medical Grand Rounds, UTMB, Galveston, TX, February 1, 2008.
242. The Latest In Spondylitis Research And Treatment. Given at the Atlanta Support Group for the Spondylitis Association of America. Atlanta, GA. February 9, 2008.